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FOREWORD 
My doctoral research investigated the participation of young people in HIV vaccine trials; 
however, my journey as a researcher started many years back when my late father told me I 
was going to be a doctor. At the time, I didn’t understand what he meant by that. When I 
graduated from medical school, I thought I had fulfilled my dad’s wishes, however that 
realization faded away as soon as I started working as a medical officer at a youth-friendly 
IDC. I was responsible for treating youths with sexually transmitted infections including 
HIV/AIDS, but importantly providing other youngsters with essential yet basic tools for 
HIV prevention. As a young doctor, I was devastated by the rampant damage to livelihood 
particularly in young people caused by HIV/AIDS. Advancing to become Monitoring and 
Evaluation Manager in an HIV care and treatment program in Dar es Salaam gave me the 
opportunity to see broader complexities of HIV burden, its determinants, dynamics and its 
prevention strategies, matters that go beyond routine clinical setting of etiology-to-
treatment modalities. I quickly jumped onto the research wagon as soon as I heard about 
HIV vaccine clinical trials at Muhimbili University of Health and Allied Sciences, MUHAS 
because, by then, I had realized that serving my people as a mere medical doctor would not 
be sufficient to alleviate the distressing impact of HIV/AIDS. I still consider joining the 
“HIV sub program” at MUHAS to be one of the best decisions I made as I knew I would be 
right in the thick of finding solutions to this frightening disease.  
My research subject “youth” was carefully chosen not only because this population is the 
most affected but also ‘forgotten’ in a sense that most HIV prevention interventions in our 
settings have been targeting adults, children and pregnant women. Since treating and 
preventing HIV have always been my top priority, research skills I have acquired during 
my doctoral training will be put into use in a quest for an effective HIV vaccine through 
research work in the field of HIV prevention.  
 
 
 
  
ABSTRACT 
Background: For nearly four decades, HIV infection has raged across the world; leaving devastation in its 
wake particularly in sub-Saharan Africa. Even though the use of antiretroviral (ARV) drugs has 
significantly contributed to lessening HIV/AIDS related morbidity and mortality, their efficacy has had a 
limited outcome on the cure and prevention of both old and new HIV infections. Like many viral diseases, 
an effective HIV vaccine is considered the cornerstone for ending the HIV epidemic. The involvement of 
young people in preventive HIV vaccine clinical trials is fundamental as they are unduly affected by the 
HIV burden. Whilst new vaccine models continue to be tested for safety, immunogenicity and efficacy, 
only a few young people join such innovative clinical interventions; highlighting an evolving need for 
understanding the intricacies of partaking in clinical HIV vaccine trials.  
Aim: The overall aim for this thesis was to increase knowledge of factors contributing to recruitment and 
participation of young people in preventive HIV vaccine trials. 
Methods: The thesis encompassed four studies using both qualitative and quantitative methods. Data 
collection for cross sectional study I was done among 450 youth using questionnaires to assess factors 
contributing to their willingness to participate in an HIV vaccine trial. Study II used seven focus group 
discussions to elicit the influence and opinions of members of the community on participation in the trial. 
In study III, we employed respondent-driven sampling to enlist 600 young female sex workers in a cross-
sectional study that assessed willingness to participate in HIV efficacy trials and risk behaviors using 
questionnaires. In-depth interviews were used in study IV to explore experiences of participating in HIV 
vaccine trials among 17 young volunteers in a phase I/II HIV vaccine trial, TaMoVac 01. 
Results: This thesis identified positive and negative attributes of the willingness of young people to 
participate in an HIV vaccine trial at several levels of ecological model. At the intrapersonal level, altruism, 
self-independence in decision making, being in charge of safe sex, having some knowledge of HIV 
vaccines and regular health check-ups were regarded as positive attributes for joining the trial whereas 
anxiety about fertility and HIV positivity post vaccination were identified constraints. Looking at the 
interpersonal level, endorsement of the trial by significant others and support of staff were features of 
partaking whereas fears of perceived contents of HIV vaccine and mischaracterization of sexual practices 
were portrayed as impediments. Last but not least, support of regulatory institutions, members of 
parliament, stigma, and the trial center were elements at the community/institutional level, while substance 
abuse, unemployment and poverty were structural factors hampering the contribution of young people to 
HIV vaccine trials.  
Conclusion: Youth showed readiness to participate in phase IIa HIV vaccine trial. For most young 
people, the decision to participate in vaccine trials largely depend on support of members of the 
community. In contrast, for high-risk young women, this decision largely be their own. Some factors like 
altruism, support from members of the community and, perceived personal benefit served as positive 
attributes to participation. Despite such readiness, fertility issues, stigma, poverty were perceived as 
hurdles needed to be resolved by different stakeholders on individual, community and societal levels for 
successful participation. 
  
Keywords: Young adults, willingness, participate, recruitment, retention, HIV, vaccine trial, phase I/II, 
Tanzania 
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1 BACKGROUND 
1.1 HIV EPIDEMIOLOGY 
1.1.1 HIV in the World  
Since its outbreak three decades ago, Human Immunodeficiency Virus, HIV has relentlessly 
continued to claim the lives of people as one of the leading causes of morbidity and mortality 
worldwide, particularly in sub-Saharan Africa, (SSA). The first HIV patients were reported in 
the United States by Centers for Diseases Control and Prevention, CDC, in 1981 among 
minority and men having sex with men, MSM, communities. Since then, new cases of HIV 
have been reported universally1.  
In 2017, UNAIDS estimated that 77.3 million people had been infected by HIV since the 
start of epidemic, and that 36.9 million people were living with HIV, of which 19.6 million 
resided in eastern and southern Africa2, accounting for 45% of the world’s HIV infections3. 
Efforts to reach targets of reducing new HIV infections, stigma and discrimination, scaling-
up of HIV prevention services, increasing enrolment of HIV-positive children in HIV 
services by 2020 have been attained to a certain degree3. The global decline in deaths from 
AIDS-related illness is at its lowest level since the outbreak of the disease in the 1980s due to 
the more widespread use of ART particularly in SSA the region. But the reduction of AIDS-
related mortality has not been quick enough to reach the General Assembly’s 2020 
milestone3. 
The number of new HIV infections globally continued to decline in 2017 yet, progress is far 
slower than what is required to reach the 2020 milestone of less than 500 000 new infections. 
The estimates have shown that new infections at all ages declined from a peak of 3.4 million 
in 1996 to 1.8 million in 2017. Children under the age of 15 years old accounted for 180 000 
new infections in 20173.  
Even though the reduction in new HIV infections between 2010 and 2017 was greatest in 
SSA due to sharp reductions in eastern and southern Africa (30% decline), this region 
remains the most affected by the HIV epidemic, accounting for 53% of people living with 
HIV globally. Other regions that have shown HIV decline include the Caribbean (18% 
decline), Asia and the Pacific (14% decline) while in the Middle East, North Africa, eastern 
Europe and central Asia, the annual number of new HIV infections has doubled in less than 
20 years3. 
Women continue to account for a disproportionate percentage of new HIV infections 
among adults in SSA, representing 59% of the 980 000 new adult HIV infections in 20173. 
Every week, around 7 000 young women aged 15 –24 years become infected with HIV 
globally. In SSA, three in four new infections are among girls aged 15–19 years, and young 
women aged 15–24 years are twice as likely to be living with HIV than men in 20172. In 
other parts of the world apart from SSA, men accounted for 63% of the 650 000 new adult 
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HIV infections in 2017. Globally, there were almost 90 000 more new HIV infections 
among men than women in 20173.  
Adolescent girls and young women continue to face a disproportionally high risk of HIV 
infection as a result of gender inequalities, gender-based violence, physiological factors3, 
insufficient access to sexual and reproductive health services, education, poverty and food 
insecurity4.  
HIV infection dominates key populations and their sexual partners. These populations 
accounted for 47% of new HIV infections globally. Ninety five percent of new HIV 
infections recorded in eastern Europe, central Asia, the Middle East and North Africa and 
16% of new HIV infections in eastern and southern Africa.  
Notably, the risk of acquiring HIV is 27 times higher among men who have sex with men, 
23 times higher among people who inject drugs, 13 times higher for female sex workers 
and 12 times higher for transgender women2. Several challenges exist in engaging key 
populations in HIV preventive services because their actions or identities are considered 
socially or religiously unacceptable, and sometimes punishable under local law. This 
impairs collection of quality data on the location and size of these populations, their 
attitudes and practices, their access to HIV services, and the incidence and prevalence of 
HIV among them in low and high HIV prevalence settings3. 
The devastating impact of HIV impinges on social, economic, health and political 
advancement worldwide but the disease’s remarkable impact is most noticeable in low-
income countries. It is estimated, for example, that 380 000 people died from AIDS-related 
illnesses in eastern and southern Africa compared to 13 000 deaths in western and central 
Europe and North America in 20172. HIV-related deaths in most low-income countries have 
led to a surge in the number of orphans, street children and children-headed family as well as 
to poor productivity and economic growth due to reduced manpower.  
1.1.1.1 Global HIV response 
The initial response to HIV prevention in 1980s was met with resistance, skepticism and 
stigma among many government officials and the community at large around the globe 
because of its association with marginalized communities, high morbidity and mortality and 
sexual transmission1. From the late-1980s onwards, international organizations began to 
realize the severity and dire consequences of HIV and hence embarked on worldwide efforts 
to fight the HIV pandemic by planning coordination meetings and developing strategies, 
policies and guidelines on the prevention of HIV1. Following that, a number of international 
donor-funded agencies, foundations and non-government organizations were created to 
provide leadership, technical support and expertise in HIV prevention particularly in 
developing countries. Through such commitment in leadership and resources, most affected 
countries had established country-specific national HIV/AIDS control programs by1995 that 
slowly over time gained local political and communal engagement. Furthermore, in 1998 the 
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discovery of antiretroviral therapy was a major scientific breakthrough that led to changes in 
the epidemiology of HIV infection globally1.  
1.1.2 HIV in Tanzania  
1.1.2.1 Country profile 
The United Republic of Tanzania is located in East Africa (Figure 1). It covers 947 300 
square kilometers5 with an overall sparse population density of 51 persons per square 
kilometer, however there are some regions with quite high population densities like Dar es 
Salaam and Mjini Magharibi6. Tanzania is divided into 30 regions: 25 on the mainland and 
five in Zanzibar. These regions are divided into districts, which are subsequently divided into 
councils. The councils or local government units administer and provide public services5. 
According to a national census, the total population in 2012 was 44 928 9236, with 97% of 
the population living on the Tanzanian mainland and the rest in Zanzibar5. The majority of 
the population, 71%, live in rural areas, whereas 29% reside in urban areas5. Youth aged 15-
24 years was found to constitute 19.1% of the total population7. The overall sex ratio was 
about 95 males to every 100 females6 and the total fertility rate was 5.5 for women aged 
between 15 and 49 years8. At the national level, the literacy rate among males aged 15 years 
and above was higher than among females, 83.4% and 73.3% respectively9,10. The gross 
domestic product (GDP) was TZS 29.5 trillion (Tanzanian shillings), an increase of TZS 4.1 
trillion on 201611. Kiswahili is national language spoken in Tanzania.  
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Figure 1: Map of Tanzania showing HIV prevalence among adults 15+ by region, 2016-
2017.  
 
Source: Ministry of Health, Community Development, Gender, Elderly and Children 
(MoHCDGEC), the Ministry of Health (MoH) Zanzibar, National Bureau of Statistics (NBS) 
and the Office of Chief Government Statistician (OCGS). Summary Sheet: Preliminary 
Findings. Tanzania HIV Impact Survey (THIS) 2016-2017. 
1.1.2.2 Tanzania health system and HIV services 
Tanzania has a well-organized health structure from the community to the national level. 
Primary health care services constitute the basis of the pyramidal structure of health care 
services, see Figure 2 below. Community-based health activities focus on health promotion 
and prevention. Dispensaries provide preventive and curative outpatient services, while 
health centers admit patients, and sometimes provide surgical services. Council hospitals 
provide medical and basic surgical services to referred patients. Regional Referral Hospitals 
provide specialist medical care. Zonal and National Hospitals offer advanced medical care 
and are teaching hospitals for medical, paramedical and nursing training. The health system is 
managed at council and regional levels by The Council and Regional Health Management 
Teams respectively. The Ministry of Health, Community Development, Gender, Elderly and 
Children, MoHCDGEC, has the overall responsibility over the health and social welfare 
services. It provides technical guidance to organizations involved in service delivery, 
mobilizes resources, controls and promotes maintenance of quality standards and sets the 
policy for social welfare12. 
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Figure 2: The health care pyramid in Tanzania (public and private equivalent)  
 
Source: The United Republic of Tanzania. Health Sector Strategic Plan July 2015 – June 
2020, HSSP IV. Reaching All Households with Quality Health Care. Ministry of Health and 
Social Welfare. 
1.1.2.3 HIV/AIDS  
HIV has enormously affected Tanzania, like so many other countries. The first HIV patient 
was reported from northern part of Tanzania, in Kagera region, in 1983. By then, HIV was 
called ‘slim’ disease due to its characteristic presentation of severe wasting due to diarrhea 
and dehydration. By December 1986, all mainland regions had reported cases to the Ministry 
of Health and Social Welfare13. HIV infections have spread throughout the country 
predominantly through unprotected heterosexual intercourse, attributing to 80% of infections, 
while mother-to-child transmission and blood borne infections account for 18% and 1.8% of 
all infections respectively14. The HIV epidemic in Tanzania Mainland is generalized and 
stable while in Zanzibar islets, it is largely concentrated. The main drivers of the HIV 
epidemic include risky sexual behaviors such as having unprotected sexual intercourse with 
concurrent multiple sexual partners, transactional and cross-generational sex, early sexual 
debut, poor and inconsistent use of condoms, poor HIV knowledge, poverty, poor coverage 
and access to HIV preventive services14, and unequal gender norms that perpetuate gender 
based violence15. In 2017, UNAIDS reported the total number of people living with HIV was 
1.5 million, out of which 120 000 were children under the age of 15, alongside an estimated 
32 000 HIV-related deaths. In the same reporting period, 65 000 people were newly 
diagnosed with HIV infection, 66% of HIV patients were alive and receiving anti-retroviral 
therapy and only 48% of them were virally suppressed3 The annual incidence of HIV among 
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adults aged 15 to 64 years in Tanzania was 0.29 percent in 201716. The overall national 
prevalence of HIV among the adult population showed a decreasing trend from 2003 to 2012, 
see Figure 3 below14. The Tanzanian HIV impact survey in 2016/2017 reported a further 
decline in prevalence to 5% among people aged 15 to 64 years, whereas prevalence among 
young people aged 15 to 24 years was 1.4%. These prevalence estimates vary with sex, age 
and regions. Among adults 15 years and older, HIV prevalence varies geographically across 
Tanzania, ranging from 11.4% in Njombe to less than 1% in Lindi and Zanzibar, see Figure 1 
above. Overall, women disproportionately bear more of the HIV burden than men, with HIV 
gender disparity more pronounced among younger adults16. 
The unrelenting impact of HIV in Tanzania has led to serious political, social and economic 
setbacks in all sectors due to increased HIV/AIDS morbidity and mortality among women 
and men in their prime years of productivity. As a result, there is poor performance in 
targeted quality of life indicators, loss of human capital, reduction of income, poverty, 
disruption of nuclear family structure, enormous strains on extended family due to orphans, 
and an increased number of households headed by children and widows17. 
Figure 3: Estimated HIV prevalence in Tanzania for the period 1980-2020 
 
 - Current estimates 2011/2012  
-Previous estimates 2007/2008 
Source: HIV/AIDS and STI surveillance report number 23. 
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1.1.3 National response to HIV epidemic. 
The Government of Tanzania has continued to demonstrate great commitment and leadership 
to the fight against the HIV and AIDS pandemic14. A major achievement was the 
establishment of the National AIDS Control Program and the Tanzania Commission for AIDS, 
TACAIDS, in 1987 and 2001 respectively5.TACAIDS took over the role of coordinating, 
overseeing, and guiding the multi-sectoral response, while the National AIDS Control 
Program, NACP, remained responsible for leading the health sector responses of the National 
Multi-sectoral Strategic Framework5 covering the period 2013/2014-2017/201814. This 
framework addresses the following fundamental thematic areas; prevention of new adult and 
child HIV infections, HIV care treatment and support, HIV/AIDS impact mitigation 
interventions, strengthening local and international partnership in the HIV/AIDS response 
and monitoring and evaluation of the HIV/AIDS response14. Additionally, a number of 
policies and strategies, such as the Global Health Initiative Strategy, the national HIV/AIDS 
communication Advocacy strategy, the HIV and AIDS care and the Treatment plan and 
health sector HIV and prevention of mother to child transmission (PMTCT) strategic plan, 
were developed and aligned to the overall health sector strategic plan to address the 
epidemic14. About eight in ten Tanzanian facilities have an HIV testing system, and one-third 
of all facilities offer HIV/AIDS care and support services. Twenty-eight percent of all 
facilities provide ART services. More than nine in ten facilities in Tanzania that offer ante 
natal clinic (ANC) services also provide some PMTCT services while other sexually 
transmitted infections (STI) services are almost universally available in Tanzanian facilities 5. 
A recent review of the health status of Tanzanians shows some improvement. Over two 
decades, there has been a downward trend in childhood and maternal mortality rates, 
improved children’s nutritional status and an increase in life expectancy at birth. These 
improvements primarily resulted from controlling the HIV/AIDS pandemic. This 
achievement was due to the provision of life-long anti-retroviral drugs and the presence of 
effective vaccination programs5. Despite the gains, there are some challenges ahead in HIV 
prevention. HIV prevalence is decreasing slowly, key populations (who inject drugs, sex 
workers and men who have sex with men) do not receive enough attention and women 
remain more at risk than men. There is also a large gap between adult and pediatric anti-
retroviral treatment coverage, a lack of age-disaggregated data to understand the situation 
regarding coverage of HIV, and sexual and reproductive health services among adolescents5. 
1.1.3.1 HIV and youth in Tanzania. 
The concept of youth varies from one community to another depending on socioeconomic 
circumstances, culture, and history. In general, a youth is a boy or girl who is in the transition 
period from childhood to adulthood. While the international definition considers youth as 
persons aged between 15 and 24 years, in Tanzania, youth refers to persons aged 15 to 35 
years18 . According to the 2012 population census data, the young population aged 15-24 
years was found to constitute 19.1% of the total population of Tanzania7. For this thesis, we 
define youth slightly differently, as 18-25 years old, because people aged 18 years and above 
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are legally and ethically allowed to sign informed consent forms. In this thesis, the term 
‘young adults’ has been interchangeably used with ‘youth’ when it comes to literature 
citations. In most cases, the term ‘young adults’ refers to both adolescents and youth because 
there is no term equivalent to ‘adolescent’ or ‘youth’ in many African languages19 . 
The Tanzania HIV/AIDS and Malaria Indicator Survey 2011-12 indicated that age at first 
sexual intercourse marks the time at which most young people risk exposure to sexually 
transmitted infections including HIV since the main route of HIV transmission is through 
heterosexual contact17. In addition, HIV infection among young people aged 14-25 is an 
important proxy gauge for determining trends in HIV incidence and prevalence14. A survey 
conducted in Tanzania in 2016/17 showed general HIV prevalence to be 1.4% among young 
adults aged 15 and 24 years (2.1% and 0.6% in young women and men respectively). This 
was slightly more than a quarter of the overall national HIV burden among the adult 
population16. Furthermore, the previous two surveys of HIV indicators compared and found 
estimates of HIV prevalence between 2007-08 and the 2011-12 in the 15-19 age group 
unchanged, at 1%17. The HIV indicator survey of 2011-12 revealed that 9% and 10% of 
women and men respectively aged 15-24 had sex before they were 15 years old. Fifty percent 
of women and 43% of men reported having sex before reaching 18 years17. In the same 
survey, among all sexually active young people age 15-24, 4% and 14% of women and men 
respectively reported having sexual intercourse with two or more partners in the past 12 
months prior to the survey17 Overall, the surveys have shown that young women are at higher 
risk of HIV infection than their counterpart males in the same age group. Some of the 
predominant HIV drivers in this age group were risky sexual behaviors, such as having 
multiple concurrent partners, living in urban areas, early sexual debut, inadequately low 
condom use and low knowledge of HIV17. 
1.2 HIV VACCINE DEVELOPMENT AND ITS INITIATIVES  
1.2.1 Global initiatives 
Use of anti-retroviral drugs for therapy and prevention, male circumcision, microbicides and 
other behavior interventions have had a significant but limited effect on the number of new 
HIV infections. The available prevention methods do not offer long-lasting protection against 
the acquisition of HIV infection. The prospects for strengthening prevention efforts have 
never been more promising, as a series of highly effective biomedical prevention tools have 
emerged in recent years to buttress the prevention benefits of behavioral and structural 
factors20. Just like many other infectious viral diseases, a safe, effective and affordable 
preventive HIV vaccine is ultimately needed to complement and enhance the effectiveness of 
existing prevention strategies to control the HIV/AIDS pandemic, particularly in low-income 
countries21. 
The scientific community has been working tirelessly and endlessly to explore different 
technologies for developing an effective HIV vaccine from as early as 1984. Initial efforts 
involved exploration of envelope-based vaccines, virus subunits, synthetic peptides, vaccinia-
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vectored vaccines, neutralizing antibodies along with the development of non-human primate 
models for HIV infection. The first HIV vaccine trial took place in the United States in 1988 
22. Thereafter, a number of early phase I/II HIV clinical trials have been recorded in the 
International AIDS Vaccine Initiative (IAVI) database23. The trials took place mostly in the 
US and other high-income countries and a few in low- and middle-income countries like 
Uganda, Kenya, Tanzania and South Africa23. Favorable outcomes to develop an effective 
HIV vaccine in clinical trials have, however, been hampered by genetic variability of HIV, 
lack of natural immunity to HIV, variability of HIV types, lack of correlates of protective 
immunity and lack of an animal model that reliably predicts vaccine efficacy in humans24.  
After studying safety and immunogenicity outcomes of vaccines in phase I/II, initial efficacy 
clinical trials were conducted but yielded disheartening conclusions. One of the first trials, 
STEP, involved the immunization of almost 3 000 healthy uninfected volunteers with three 
adenovirus vectors, each expressing an HIV gene of a vaccine. The STEP trial was designed 
to elicit strong cellular immunity but, nonetheless, it showed no protection against infection. 
More alarmingly, the vaccine appeared to increase the rate of HIV infection in individuals 
with prior immunity against the adenovirus vector used in the vaccine. In addition, the same 
vaccine was being administered in South Africa to 3 000 individuals in the Phambili trial 
when the initial results of the STEP trial were made public. Since no one could have 
predicted the correlation between preexisting vector-specific immunity and an increase in 
susceptibility to HIV infection, the results lead to the immediate halting of both the STEP and 
Phambili trials25. 
Nevertheless, in 2009, results of HIV clinical trials involving 16 402 Thai men and women 
at mostly heterosexual community risk of HIV-1 provided the first breakthrough and 
demonstration in humans that a vaccine can prevent HIV infection. Two HIV vaccine 
candidates showed a vaccine efficacy in preventing HIV infection among the volunteers, 
60% and 31% efficacy at 12 months and 3.5 years respectively. The vaccine efficacy was 
higher among those whose initial self-reported risk was low and did not change during the 
trial. It was lower among those whose risk was not low at baseline and/or increased during 
the trial26. That breakthrough gave researchers a platform to improve research activities to 
further study immune response, methodology and administrative approaches of RV144 in 
order to improve the design of future trials24. 
Based on RV 144 trial results, in November 2016, a large phase IIb/III HIV vaccine clinical 
trial, HVTV 702, was launched among 5 400 seronegative South African adults over 24 
months and potentially up to 36 months from enrollment27. The HVTN 702 study is the 
largest, phase IIb/III advanced stage clinical trial to take place in South Africa that aims to 
determine if an investigational HIV vaccine regimen is safe, tolerable and effective at 
preventing HIV infection among South African adults. The experimental vaccine regimen is 
based on the one tested in the RV144 clinical trial in Thailand. The HVTN 702 vaccine 
regimen has been adapted to the HIV subtype that predominates in southern Africa, where the 
pandemic is most pervasive28.  
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1.2.2 Tanzanian initiatives  
In the 1990s, Tanzania started to prepare its sites for early-phase HIV vaccine trials by 
conducting incidence and prevalence studies to assess the suitability of police officers for 
trials29,30. The researchers trained laboratory and clinical personnel; and developed and 
established virological and immunological methods for vaccine immunogenicity assays in 
collaborating laboratories in Sweden and Tanzania31. The preparations paved way for a phase 
I/II clinical trial (HIVIS03) with 60 healthy HIV negative volunteers in Dar es Salaam, 
Tanzania. The aim was to continue evaluating the safety and immunogenicity of multiclade 
HIV-1 plasmid DNA vaccine followed by MVA boost with heterologous HIV-1 inserts. The 
vaccine demonstrated excellent safety and immunogenicity by eliciting cell-mediated and 
antibody responses to Env-antibody responses31. Following the success of the HIVIS 03 trial, 
between 2010 and 2012, a phase IIa randomized clinical trial, TaMoVac 01, recruited 120 
healthy, low-risk, HIV-negative participants from two centers in the Dar es Salaam and 
Mbeya regions. In Dar es Salaam, these participants were police officers and prison service 
officers, as well as young people from a youth friendly IDC and in Mbeya, they were from 
the general population32. In this trial, investigators found that a simplified intradermal 
vaccination regimen with 2 injections of combined HIV-DNA plasmids primed cellular 
responses was as efficient as the standard regimen of 5 injections of separated plasmid pools 
after boosting twice with HIV MVA. In the aftermath, the TaMoVac II phase II clinical trial 
was carried out between 2012 and 2015 to assess the safety and immunogenicity of DNA 
priming administered by electroporation, as it was hypothesized that electroporation would 
increase immune responses and thereby the efficiency of DNA priming and lead to a dose-
sparing DNA vaccine regimen. This would in turn reduce the number of shots necessary to 
deliver the full dose and induce comparable immune responses as is the case with lower DNA 
vaccine concentrations33. 
1.3 RATIONALE 
Generally, young people are disproportionately affected by the burden of HIV/AIDS and 
AIDS-related death, thus they need to be included in HIV vaccine trials. AIDS is the leading 
cause of death among young people in Africa34. Young women are twice as likely to acquire 
HIV infection than young men because of early sexual debut, poor condom use, sexual 
violence and have less comprehensive knowledge of HIV35. Furthermore adolescent girls and 
young women are often prevented from seeking services and making decisions about their 
own health due to gender inequalities34. The vulnerability is further fueled by laws and 
discrimination of young people in key populations such as female sex workers, young men 
having sex with men, and intravenous drug users35. The inclusion of youth in HIV prevention 
clinical research has the potential to improve the current understanding of the safety and 
efficacy of biomedical prevention technologies in younger populations that are at increasing 
risk of HIV infection. However, there are significant individual, operational, and community-
level barriers to engaging youth in clinical prevention trials. Such barriers include insufficient 
understanding of clinic prevention research, self-presentation bias, access to clinical trials, 
mistrust of research, and stigma associated with participation in clinical trials36.  
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Moreover, HIV vaccine trials are shrouded in negative attitudes and personal fears from 
significant others37, misconceptions such as that the vaccine will cause HIV infection, or, 
conversely, that the vaccine in a trial will protect from HIV infection 38 leading some 
participants to see participation in a vaccine trial as an opportunity to stop using HIV 
prevention strategies such as condoms and partner reduction39. Another possible barrier to 
youth participation in HIV vaccine trials emerged in a study on men who have sex with 
men, where participants worried that vaccine-induced seropositivity, VISP, would be 
interpreted by society as actual HIV infection and entail the same level of stigma40. 
 
Whereas involving youth in multistage HIV vaccine trials with many follow-up visits is 
crucial, very little has been investigated as regards the challenges pertaining to recruitment 
and participation in Tanzanian settings. In light of this, we studied issues surrounding the 
willingness of young people to be recruited, experiences of young volunteers in an early-
phase HIV clinical trial, as well as tried to elucidate the role and opinions of significant 
others towards youth participation in HIV vaccine studies in order to add some knowledge 
to the existing literature. The findings from this project may contribute to shaping a national 
HIV vaccine framework, strategies and policy and help to address challenges pertaining to 
recruitment, participation as well as the implementation of future HIV vaccine studies 
among young people in Tanzanian settings. 
2 AIM AND OBJECTIVES 
General aim: 
To increase knowledge of factors contributing to recruitment and participation of young 
people in preventive HIV vaccine trials. 
 
Specific objectives: 
 
I. To characterize the willingness of young adults in Tanzania to participate in a phase I 
and II HIV vaccine trial and identify the factors that influence this willingness.  
II. To explore the views of members of the community on participation of youth in an 
HIV vaccination trial. 
III. To describe the recruitment approaches, risk behaviors and practices and willingness 
of young female sex workers to participate in efficacy HIV vaccine trials. 
IV. To investigate experiences among young adult volunteers who participated in a phase 
I and II HIV vaccine trial. 
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3 METHODS 
3.1 SUMMARY OF STUDIES IN THESIS 
 
What are the views of 
community members on the 
participation of young people in 
HIV vaccine trials? 
 
Pre-
Trial 
Post-
Trial 
How to describe the sexual 
behaviors of young female sex 
workers and factors influencing 
their willingness to participate in an 
HIV vaccine trial? 
What are the factors affecting 
the willingness of young people 
to participate in an HIV vaccine 
trial? 
What are experiences of being 
a trial participant among 
young volunteers in the HIV 
vaccine trial? 
 
Quantitative 
cross-sectional 
survey 
 
Qualitative 
 
Structured 
interviews with 
450 young 
people 
Focus group 
discussions 
17 members 
of the 
community 
I 
Quantitative, 
cross-sectional 
survey using 
RDS 
 
II 
Structured 
interviews with 
600 young 
female sex 
workers 
III 
Qualitative 
 
In-depth 
interviews 
with 17 young 
volunteers in 
the TaMoVaC 
I HIV vaccine 
trial  
IV 
Domain 
Research 
questions 
Study 
design 
Data 
collection 
& study 
population 
Paper 
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This thesis included our sub-studies that used both quantitative and qualitative methods to 
answer research questions surrounding the factors influencing participation of youth in 
preventive HIV vaccine trials in Dar es Salaam, Tanzania. Quantitative research is research 
that places emphasis on numbers in the collection and analysis of data41. In this thesis, it was 
used to quantify, describe and characterize the youth willing to be recruited to HIV vaccine 
trials, whereas a qualitative method was employed to seek in-depth understanding of the 
research gaps in cultural issues and the social support contextual settings of HIV vaccine trial 
participation among young people 42. Both methods complemented each other to generate 
deeper understanding and a contextual explanation of outcomes of interest in the thesis.  
3.2 SETTING 
The Dar es Salaam region is found along the coast of Tanzania (see Figure 1). According to 
the 2012 national census, this region was inhabited by a total of 4.3 million people, of whom 
51.3% were female. Its population growth rate per annum was 5.6. The literacy rate of people 
aged 5 years and above was 93.6%. It is one of the biggest business cities in Tanzania that is 
involved in tourism, business, fish farming, livestock and poultry43. The region has been 
divided into five administrative municipalities: Kinondoni, Ilala, Kigamboni, Ubungo and 
Temeke. There is one national referral hospital, Muhimbili National Hospital, in Ilala, with 
five referral hospitals in all 5 municipalities. For years, Muhimbili National Hospital has 
served as one of the major teaching hospitals, and recently a new teaching hospital, the 
Muhimbili University of Allied Health and Sciences Academic Medical Centre, has been 
opened in Ubungo district. Apart from that, Dar es Salaam has a number of government-
owned district hospitals, health centers, dispensaries, as well as health facilities run by faith-
based, private and non-government organizations. 
3.3 STUDY PARTICIPANTS 
All study participants were recruited from all districts of Dar es Salaam region, mostly 
females aged 25 years or less. Most of them had completed seven years of basic primary 
school education and were single. In study I, the young adults visiting the youth friendly IDC 
for medical consultation, health education, family planning services, HIV counselling and 
testing consented to participate. In study II, the participants were community members, such 
as parents, guardians, friends, peers and siblings, whom were identified by the young people 
who took part in study I. The community members participating in study II were close to the 
young people and played important roles in providing social support. In study III, young 
female sex workers who had provided sex in exchange for money, drugs or gifts in the past 6 
months were recruited. Study IV included the young volunteers who received the first three 
doses of HIV 1 DNA vaccines or placebo injections in the HIV vaccine trial, TaMoVac 01.  
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3.4 STUDY DESIGNS  
3.4.1 Cross-sectional studies 
3.4.1.1 Study I 
Study I was a cross-sectional study using a self-administered questionnaire, written in 
Kiswahili, among 450 youth at an Infectious Disease Clinic (IDC). This IDC is a government 
facility located in Ilala Municipality that provides youth-friendly health care services such as 
screening and treatment of sexually transmitted infections, contraceptives, counselling, 
testing, care and treatment for HIV. In 2012, a total of 4,379 individuals, 28% of whom were 
young people, aged 12-25 years, visited the IDC. Most of the newly registered attendees 
sought HIV counselling and testing followed by treatment of other STIs. The participants of 
the study were all individuals aged 18-25 years who visited the IDC from February to 
September 2012. Of the 548 youths approached, 98 (18%) did not accept this invitation, 
primarily because of time constraints. The participants were then systematically selected by 
including every other patient. For those who declined, their replacements were selected in the 
same manner until we reached the required sample size. Each participant filled out a written 
consent form, then answered research questions in the questionnaire with minimal 
supervision from research assistants.  
3.4.1.2 Study III 
Study III was a cross-sectional study using a self-administered questionnaire among 600 
young female sex workers recruited using the respondent-driven sampling (RDS) strategy. 
The study examined recruitment approaches, risk behaviors and willingness of young female 
sex workers to participate in an efficacious HIV vaccine trial. The RDS strategy was used in 
order to facilitate recruitment of hard-to-reach participants by using a dual incentives system 
that compensated a participant both for being interviewed and for recruiting others to the 
study44. The study was based on the findings of a formative study conducted among 15 
participants between November and December 2016 using in-depth interviews. The 
formative session was conducted so as to establish hot spots, the scheduling of visits at trial 
centers, perceived stigma and barriers to health-seeking behaviors. Initially, 10 of 15 key 
participants were identified as seeds/initial recruiters, eventually the number of seeds 
increased to 20 because some initial recruitment chains ceased early by not referring their 
peers to the study site. The seeds recruited the first wave of study participants. Each of the 
seeds and subsequent recruiters received three coupons with unique serial numbers. The 
following instructions were given to the recruiters: to recruit female peers and friends aged 
between 18 and 25 years, the peers/friends who exchanged sex for goods, gifts or money 
within their circle and recruit the girls the recruiters had an idea about where they lived. The 
recruiters were further asked to observe a deadline for the date of return of valid coupons 
given to recruited participants. Finally, the research assistants discussed with them about the 
nature of compensation, i.e. compensation of transport allowance and time as a recruiter after 
bringing eligible participants for enrolment in the research. Thereafter, each referred 
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respondent received three coupons, and recruited their peers until the sample size was met. At 
the clinic, each referred respondent voluntarily presented herself with a valid coupon, signed 
a consent form and filled in a questionnaire. The participants were provided with counseling 
on STI risk reduction such as HIV and contraceptive use. They were offered HIV counselling 
and testing at the clinic. Those who were HIV-positive were referred to care and treatment at 
the IDC or other center of their choice. 
3.4.2 Qualitative studies 
3.4.2.1 Study II 
Study II was a qualitative study focused on perceptions and roles of members of community 
regarding the participation of youth in HIV vaccine trials based on the findings of study I. 
Some participants in study I were asked to refer one person who played a key supportive role 
in their life. The participants for study II included peers, friends, siblings, parents and 
guardians, collectively referred to as members of the community. They formed a group with 
different socio-demographic information and backgrounds. Study participants were recruited 
using purposeful sampling to obtain participants with the wealth of information required to 
answer research questions45. The study participants were initially contacted about the study 
by the respective young person, thereafter, a research team made formal contact. All potential 
study participants were informed about the aim of the study, venue, form and nature of 
meeting.  
3.4.2.2 Study IV 
Study IV was a nested, qualitative study exploring positive and negative experiences among 
all young adults who had completed three HIV 1 DNA/placebo vaccinations in an HIV 
vaccine trial. The study participants were among the volunteers in the main HIV vaccine trial 
named TaMoVaC 0132. For the purpose of Study IV, out of 25 young volunteers in TaMoVac 
01, only 17 volunteers were reached and consented to participate in the study. We were not 
able to recruit another 8 volunteers because some were not in Dar es Salaam at the time of 
interview, others were sick and others could not be reached by mobile phone. Data collection 
was done through in-depth interviews using semi-structured interview guide because 
interviews give detailed information about a person’s thoughts and behaviors and can also 
lead to in depth exploration of new issues. The interviews furthermore provide context to 
other data, offering a more complete picture of what happened in the program and why46. 
3.4.2.3 Steps of recruitment of young adults in the phase I/II HIV vaccine trial, TaMoVac 
01 
For the larger HIV clinical trial, the TaMoVac 01 trial, the potential young volunteers were 
informed of it at different youth NGOs such as KIWOHEDE, UMATI and SALVATION 
ARMY so as to sensitize youth, their teachers, trainers and guardians to HIV prevention 
lessons. Young people who showed interest in HIV prevention sessions were invited to the 
youth friendly IDC. At the IDC, the potential volunteers were given a health education 
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information package focusing on HIV prevention messages, contraception use, STI 
management, HIV counselling and testing, adolescence and reproductive health and HIV 
vaccine trial participation among youth. After the first session, the participants were asked to 
fill in forms to obtain their demographic and contact information. Further, the participants 
were asked to indicate if they would want to come to a second educational session which 
focused on HIV vaccine trial participation among youth. During the second session, usually a 
week after the first session, interested participants came to the IDC specifically to receive 
information on HIV vaccine trials. Among the things discussed were history of vaccines, 
stages of vaccine production, inclusion and exclusion criteria in clinical trials, benefits and 
expected adverse events, clinical trial schedule, need for contraceptive use during the trial 
period and inclusion of significant others during the trial. At the end of the second session, 
participants who were interested to join in the clinical trial were registered and asked to come 
to the third session with people whom they regarded as significant in their decision making 
and who played other key roles in the provision of social support. During the same session, 
more detailed information on the HIV vaccine clinical trials was provided including type of 
investigations, amount of blood drawn per visit and HIV risk assessment. In these sessions, 
potential trial participants had the opportunity to obtain accurate information about trial 
processes and answers to myths about HIV vaccine trials. After the educational sessions, 
those who were willing to participate in and thought to be eligible for trials were given 
informed consent forms. The potential volunteers were asked to take the consent forms, read 
and share the information with their significant others and to return with the forms at the 
following scheduled meeting. Finally, the potential volunteers presented themselves at the 
trial center in Muhimbili National Hospital to start formal recruitment procedures, including 
the review and signing of consent forms to ensure the potential participants understood what 
it entailed to be trial participant, review of individual inclusion and exclusion criteria, risk 
assessment and to take samples for investigation. In sum, the TaMoVac I trial in Dar es 
Salaam recruited 60 healthy HIV-negative volunteers, of which 25 were young volunteers 
aged 18-24 at the time of recruitment32.  
3.5 DATA COLLECTION TOOLS 
3.5.1 Structured interviews  
Structured interviews were employed to conform to a standardized list of questions, sequence 
of questioning and systematized ratings of the responses of the study participants. Structured 
interviews improve validity, reliability and coverage of interviewees and reduce variability47. 
In studies I and IV, the standardized structured interviews using questionnaires had both 
open- and closed-ended questions. The open-ended questions were used as follow up 
questions to the closed-ended questions. The open-ended questions were used to get more 
information and meaningful explanation of the responses to some key closed-ended 
questions. In study I, the questionnaires comprised of questions on sociodemographic 
information of the study participants, sexual risk assessment, contraceptive use, knowledge 
about and perception of HIV vaccine studies, presence and type of social support that young 
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people would need or have when they decided to join HIV vaccine trials and willingness to 
participate in HIV vaccine trials. 
In study III, firstly, participants filled in the questionnaires for assessing social network size, 
tracking of recruiter-recruit relationship and reasons for accepting the coupons. That was 
followed by a standardized behavioral assessment questionnaire for assessing the 
sociodemographic information of the study participants, risk behaviors, willing to participate 
in efficacious HIV vaccine trials, people within sexual networks who might influence their 
participation in the vaccine trials and other practices of using HIV prevention methods. 
In both studies, participants filled questionnaires by themselves in order to give them the 
opportunity to answer truthfully some of the sensitive information, hence minimizing the 
negative impact of social desirability. However, the completed questionnaires were 
immediately reviewed by trained research assistants, who were trained and registered nurses. 
The research assistants helped to provide guidance to participants on questions that were 
unclear, counsel participants in case of discomfort, or guide them on completion of the 
questionnaires. 
3.5.2 Focus group discussions 
A focus group is a technique involving the use of in-depth group interviews in which 
participants are selected because they are a purposive, although not necessarily 
representative, sampling of a specific population, this group being ‘focused’ on a given 
topic”48. Participants in this type of research are selected on the criteria that they would have 
something to say on the topic, are within the age-range, have similar socio-characteristics and 
would be comfortable talking to the interviewer and each other49. In study II, to preserve 
homogeneity, the groups were separated by gender so as to ensure freedom of discussion 
among members49. The participants were divided into a total of seven male and female only 
groups; comprising of three and four groups of women and men respectively. Each group had 
between five and eight participants. The FGD guide was used to ensure consistent flow of 
thoughts hence enabling meaningful flow of discussions. During sessions the PhD candidate 
TM and co-author EAMT moderated the sessions interchangeably to keep discussions within 
topic and ensure every member had equal opportunity to express their view. The guide 
included socio-demographic information and three leading questions: 1. What impedes young 
people from participating in clinical trials? 2. How would you support such participation? and 
3. What other facilitating factors might promote participation? A total of seven group 
discussion were conducted, to reach saturation50. All discussions took place at IDC. The 
duration of each session was approximately 30 to 67 minutes, and each was audio-recorded 
after obtaining permission from the participants.  
3.5.3 In-depth interviews 
In depth interviews were conducted for Study IV using a semi-structured interview guide. 
They give detailed information about the interviewee’s thoughts and behaviors and can also 
lead to an exploration of new issues in depth. The interviews furthermore provide a context to 
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other data, offering a more complete picture of what happened in the program and why46. For 
this study, a semi-structured interview guide was used to bring an interviewee into discussion, 
thereafter letting them describe their positive and negative experiences as an HIV trial 
participant in the Kiswahili language. The interview guide probed about the meaning of being 
a trial participant, reasons for volunteering, coping with follow-up visits, phlebotomy 
(injections & taking blood samples), and views on fertility, contraceptive uses, risk 
perception, sex practices during and after trial, benefits and challenges of trial participation, 
and the role of social support. All 17 interviews were conducted in a room with a door and 
windows covered by curtains to maintain privacy so as to provide the most comfortable 
environment possible. The interviews lasted about 45 minutes each, they were all audio-
recorded after permission had been sought from the interviewees beforehand.  
3.6 DATA ANALYSIS 
3.6.1 Quantitative analysis  
3.6.1.1 Logistic regression (Study I) 
Double data entry for 450 questionnaires was carried out in an EpiInfo database. Two data 
sets were merged, compared, and cleaned. The frequency distributions of all socio-
demographic and independent variables were determined. The proportion of young people 
who were willing to participate in an HIV vaccine trial was determined. Assessment of 
perceptions of HIV vaccine studies was conducted by 8 Likert like statements with 4 
responses: strongly agree, agree, disagree and strongly disagree, which were scored as 4, 3, 
2, and 1 respectively for positively phrased statements. In negatively phrased statements, 
the order of scores was reversed to reflect the scores above. The Cronbach alpha coefficient 
was 0.64, reflecting relatively low internal reliability of the statement in measuring 
perception51. However, we included this analysis because at individual level these questions 
collected information that was critical to understating how participants felt about HIV 
vaccine studies. The median total score for each statement for all participants was 22. This 
categorized perception of HIV vaccine studies as positive for any score of 22 and above and 
negative for any score less than 22. The assessment of knowledge concerning HIV vaccine 
studies was done by asking six questions. The questions investigated the concept of placebo 
versus vaccine, infectivity, safety, and protection afforded by the HIV vaccines. They were 
not standardized questions, but we formulated them based on needs that arose after a 
literature review of the knowledge of HIV vaccine studies among young people revealed 
limited awareness of the subject. The internal reliability of 0.6 was determined using 
Cronbach alpha coefficient. Despite the fact that it was low, the aggregate variable of 
“knowledge concerning HIV vaccine” was included in the analysis. Responses to questions 
were scored as 1 when answered correctly and 0 for incorrect answer or ‘I don’t know’. The 
mean total possible score out of 6 was 2.1. Therefore, this variable was categorized as 
having some knowledge for all participants with scores at or above the mean, and low 
knowledge for those with less than the mean score.  
Using Chi square tests, bivariate analyses were performed to examine the associations 
between gender and sexual behavior, then willingness to participate with socio-
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demographic characteristics, sexual behavior, social support, perceptions and knowledge 
concerning HIV vaccine studies. Logistic regression models were employed to control for 
cofounders as follows: all bivariate analyses of willingness to participate with a p-value of 
less than 0.2 were included in multivariate logistic regression analyses and were considered 
to be statistically significant if the resulting p-value was less than 0.0552. The Hosmer-
Lemeshow goodness of fit test was applied to assess the logistic regression model, and a 
final p-value of less than 0.05 was taken as indicating good fit. The frequency of missing 
data was 3.3%. All statistical analyses were two-sided and performed using Stata Version 
12.1 for Windows.   
3.6.1.2 RDS and Logistic regression (Study III) 
We conducted double data entry to minimize data entry errors. Two data sets were compared 
to identify errors, which were corrected using the unique RDS and registration numbers in 
source documents. Preparation of data for analysis was done by coding variables such as age 
groups into categorical variables, and aggregating some variables into one category e.g. 
widow and divorced. Moreover, other categorical and binary variables whose responses were 
in word format were changed into numeric values53. The data analysis started by using the 
RDS-SS Analytical package54 because in RDS, the sample is used to make estimates about 
social network connecting the population, then, using information about social network size, 
estimates are generated about characteristics of the population55. 
Weighted frequencies of the population proportions of selected variables of interest were 
compared with unweighted ones. Furthermore, 95% confidence intervals of weighted 
population proportions were calculated using the RDS-SS Analytical package54. Using the 
STATA 13/SE package, and considering the weighting and clustering, the bivariate 
associations of willingness to participate in HIV vaccine trials using selected independent 
variables such as sociodemographic characteristics, risk behaviors and power dynamics in 
sexual networks, were determined by computing weighted data in regression models56. All 
those associations of the willingness to participate and variables with P value of ≤ 0 .25 were 
entered into the final model to look for factors associated with willingness to participate in 
trials57. The results of logistic regression models were presented as odds ratios with 95% 
confidence intervals. Thereafter, all variables that had P value of ≤0.05 were regarded as 
statistically significant in the final model.  
3.6.2 Qualitative analysis 
3.6.2.1 Content analysis (Study II) 
The purpose of content analysis is to organize and elicit meaning from the data collected and 
to draw realistic conclusions from it. The researcher must choose whether the analysis should 
be of a broad surface structure (a manifest analysis) or of a deep structure (a latent analysis)58. 
During the analysis, each transcript from seven focus group discussions constituted a unit of 
analysis58. During analysis, recordings were transcribed verbatim, with final Swahili 
transcripts translated to English. Using content analysis, the results were expressed primarily 
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as manifest and latent content. The views of members of community were abstracted from 
sentences having similar meanings in the transcripts to form meaning units. Here, a meaning 
unit refers to words, sentences or paragraphs containing aspects related to each other through 
their content and context 59. The meaning units were then coded using different colored codes 
within the transcripts. The codes having similar thoughts and meaning were further organized 
and abstracted into categories. A category refers mainly to a descriptive level of content and 
can thus be seen as an expression of the manifest content of the text59. Finally, three themes 
emerged from summarized categories that contained the same concepts. In this analysis, a 
theme was considered as a thread of an underlying meaning through condensed meaning 
units, codes and categories, on an interpretative level, seen as an expression of the latent 
content of the text 59. 
3.6.2.2 Interpretive descriptive analysis (Study IV) 
Data analysis was conducted using the interpretive description approach as this is an 
inductive analytic approach designed to create ways of understanding clinical phenomena 
that yield applications implication60. The foundation of interpretive description is the 
smaller scale qualitative investigation of a clinical phenomenon of interest to the discipline 
for the purpose of capturing themes and patterns within subjective perceptions and 
generating an interpretive description capable of informing clinical understanding. 
Interpretive description departs from traditional qualitative descriptive approaches in that it 
assumes investigators are rarely satisfied with description alone and are always exploring 
meanings and explanations that may be adapted in clinical settings. Simply stated, 
interpretive description provides direction in the creation of an interpretive account that is 
generated on the basis of informed questioning, using techniques of reflective, critical 
examination, and which will ultimately guide and inform disciplinary thought in some 
manner61. Using this approach in Study IV, data was transcribed from all the verbatim 
audio-recorded data, with the transcripts translated from Kiswahili to English. PhD 
candidate TM familiarized herself with data by reading all transcripts in both languages to 
ensure transcribed and translated texts had captured all the information as described by the 
participants. All transcripts were broken into small paragraphs that described similar 
concepts to obtain meaning units, which described the core meaning of each paragraph. The 
meaning units were then examined and assigned to groups of similar patterns or codes. 
Different colored papers were used to identify different codes within the transcripts. This 
was a descriptive part of analysis whereby the transcripts were naturally labelled as they 
were initially explained. Similar codes were then discussed, contextualized and grouped 
into categories. Finally, after examination, rearrangement and sorting of similar categories, 
two themes emerged inductively based on data, and not on a pre-existing analytical 
framework. Throughout this process, raw data was conferred to ensure that researchers’ 
interpretations were coming from the data. The emerged themes portrayed the living 
experiences of being a young trial participant. The member check was done by holding a 
debriefing meeting with some participants. During the meeting, PhD candidate TM 
presented the findings and their meaning as per researcher’s perspectives. The participants 
were given opportunity to discuss and interpret findings in their own words. At the end, all 
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participants agreed that the findings of this investigation echoed the experiences of the 
young people participating in the trial. 
3.7 ETHICAL CONSIDERATIONS 
The studies were granted ethical approval by the Institutional Review Board at Muhimbili 
University of Health and Allied Sciences (MUHAS) as follows: studies I&II 
MU/DRP/AEC//Vol.XIV/33 dated 31st October 2012, study III 2017-04-12/AEC/Vol.XII/78 
dated 12th April 2017 and, study IV MU/DRP/AEC/Vol.XVI/100 dated 28th February 2013. 
Permission to use IDC as a venue for data collection was granted by the relevant authorities. 
Study participants were informed of the aim of the studies, the need for participation, their 
right to withdraw at any time and the benefits and risks of participating. The researchers and 
research assistants were available to clarify additional questions before the participants 
decided to sign the consent forms. All potential participants signed the consent forms before 
taking part in the respective studies. 
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4 RESULTS 
In general, the findings will be discussed in a modified socio-ecological model to explain the 
intertwining of factors at different level that positively and negatively affect the participation 
of young people in preventive HIV vaccine trials in Tanzanian settings.  
The socio-ecological model, SEM, was proposed by McLeroy et al62, who describe it as a 
model for health promotion and disease prevention. For this project, the model explains HIV 
vaccine trial participation among youth as a health promotion entity to prevent the acquisition 
of new HIV/AIDS infection. The model looks at both individual and environmental factors as 
targets for health promotion interventions to address changes in intrapersonal, interpersonal, 
organizational, community and public policy in order to maintain health behaviors. 
Furthermore, the model assumes that changes in social environment will bring changes in 
individuals, and that support of individuals in population is necessary for implementing 
environmental changes as detailed below: 
• Intrapersonal factors describe characteristics of individuals such as knowledge, 
attitudes, behavior, self-concept and skills, including the developmental history of the 
individual.  
• Interpersonal processes and primary groups refer to formal and informal social 
networks and social support systems, including family, work groups and friendship 
networks. 
• Institutional factors include social institutions with organizational characteristics and 
formal rules and regulations for operation. 
• Community factors refer to relationships among organizations, institutions and 
informal networks within defined boundaries. 
• Public policy describes local, state and national laws and policies. 
In this thesis, our results have been organized and discussed in terms of intrapersonal factors, 
interpersonal processes, institutional/community and structural/policy factors as illustrated in 
figure 4 below. 
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Figure 4: Modified socio-ecological model illustrating factors for the participation of the 
young people in the HIV vaccine trials, adapted from McLeroy et al.  
 
 
 
4.1 CONTRIBUTORY FACTORS IN THE RECRUITMENT AND 
PARTICIPATION OF YOUTH IN PREVENTIVE HIV VACCINE TRIALS 
4.1.1 Intrapersonal factors 
In study I, intrapersonal elements associated with the recruitment of youth in HIV vaccine 
trials included: being 15 or older at the time of sexual debut (AOR for age groups 15-19 years 
and older participants 2.6 (95% CI 1.0-6.7) and 2.7 (95% CI 1.0-7.1) respectively; having 
some knowledge about HIV vaccine studies (AOR 2.1, (95% CI 1.5-3.4); and a positive 
perception of such studies (AOR 2.3, (95% CI 1.5-3.6). In study III, almost all respondents, 
545 (91%), responded positively to a question on willingness to participate in a hypothetical 
HIV vaccine trial. Some of the reasons given for wanting to participate in an HIV vaccine 
trial were altruism (20%), wanting to contribute to a cure for HIV and wanting to learn about 
vaccine trials. Furthermore, the participants expressed some degree of autonomy in decision 
making, as 61% of the participants did not need permission from anyone to participate in a 
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trial. In Study IV, participants reported that during educational sessions they were told about 
regular checkups during the trial period. This, coupled with the fact that the services would be 
provided on a regular basis, attracted them to join the HIV vaccine trial, TaMoVac 01, as 
illustrated below: 
“I wanted to know my overall health status as one would be checked every now 
and again, (Female participants, TMV 2)”, others cited “I just wanted to have 
regular HIV and pregnancy tests during trial”, TMV 9. 
Furthermore, participants in Study IV reported being eager to know how vaccine trials were 
conducted as a reason for joining the trial. One explained as follows: 
“To know whether or not the vaccine would have ill-effects, how effective it 
would be in the human body as well as understand what the research was all 
about”, TMV 10. 
In Study IV, positive attributes leading to participation and staying in the HIV vaccine trials 
included gained health knowledge during trials. Here, the participants stated that they 
acquired knowledge, which helped them to dispel myths and suspicion about the trial. 
Knowledge made the participants confident and resilient, two qualities needed not only to 
stay but also to complete the trial as illustrated below:  
“I got the chance to understand a great deal about HIV and family planning. The 
participation turned me into a different young person. I am young and there are many 
temptations that we, youth, come across. I am afraid I might have been swept off my 
feet and keep bad company if I had no help in the form of advice from staff” 
(Informant 8, unmarried female, 23 years old). 
Participants reported that having regular feedback from the results of different clinical 
investigations during trial made them aware of how the body worked. This lessened their 
initial fears of receiving test results, and assured them that they were in good health as 
expressed below:  
“I got a lot of self-confidence as opposed to the time before trial when it came to 
testing for HIV, but now I am full of confidence” (Informant 16, unmarried female, 22 
years old). 
Participants in study IV stated that the availability of condoms at the trial center made them 
feel they were in charge of safe sex. The use of condoms was regarded as safer sex behavior 
because of its dual protection from both sexually transmitted infections, including HIV, and 
unplanned pregnancy. The latter conditions, if they had occurred during the trial period, 
would have led to discontinuation of the vaccination schedule. Participants felt that the trial 
provided them a good excuse not to get into parenthood because some of them were not ready 
for it. At the same time, they were able to negotiate safe sex with their partners as conveyed 
by the following statement: 
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 “We used condoms for both purposes - protecting ourselves against STIs and 
avoiding the possibility of her getting pregnant” (Informant 5, unmarried male, 24 
years old). 
For those with no children, condom use was a means of delaying parenthood and for those 
who had children, they described condom use as a means of spacing children. This was 
expressed as: 
“I found pregnancy prevention was a good thing. To begin with, I already have a 
child. What do I need another one for? In fact, the father himself is a problem - so 
why get another child?” (Informant 16, unmarried female, 22 years old). 
In addition, male participants saw condom use as a more reliable family planning method 
than other methods because other methods were under the control of their partners. This was 
expressed as follows:  
“I believe in condoms because women forget to take the pill, but also in today’s 
world, girls want to use pregnancy as a means of trapping men” (Informant 3, 
unmarried male, 25 years old). 
In contrast to the above, negative attributes such as fertility issues and false HIV positivity 
post vaccination were mentioned as barriers that may had contributed to not participating and 
hence poor retention in vaccine trials. In Study IV, participants struggled to maintain the 
balance of, on the one hand, fulfilling expectations from their community to reproduce and, 
on the other hand, as the trial participants, not conceiving during the trial period. For some 
married participants, disclosing avoidance of pregnancy to spouses during the trial period was 
difficult because some spouses were not aware of participants’ involvement in the trial. Other 
participants felt their spouses would suspect them of having extra-marital affairs if condoms 
were to be used, as expressed in the following statement: 
As a vaccine participant, I decided not to get pregnant; but I got pregnant because I 
was not using any family planning method and my husband did not know I was a trial 
participant. The pregnancy left me perplexed; I stopped visiting clinic because we 
were told very clearly that we should not get pregnant (Informant 4, married female, 
26 years old). 
Another participant added:  
“Unfortunately, I made my girl pregnant during the trial because using condom in a 
steady relationship appears as being unfaithful” (Informant 12, married male, 23 
years old). 
 
Apart from the above, fear of being falsely ‘HIV-positive’ due to vaccination came up as a 
concern during participation in the HIV vaccine trial. The participants admitted to 
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understanding the meaning of being falsely HIV-positive post vaccination, but even with that 
understanding, their fear of being seen as ‘HIV-positive’ after vaccination was genuine, as 
narrated below: 
“I am afraid of testing for HIV after trial because a percentage of participants have 
been found to be HIV-positive after the completion of the research. I do not know 
whether or not showing that vaccine trial participation card would make them take 
another type of test after the first one has come out positive” (Informant 9, unmarried 
female, 22 years old). 
4.1.2 Interpersonal factors 
Interconnection of positive social networking among young people, parents, clinical team, 
peers, friends, guardians and friends was shown to be imperative to participation of youth in 
HIV vaccine trials. In the Tanzanian context, having social supportive system was one of the 
important components in the recruitment of youth in HIV vaccine trials. In all studies, it was 
clearly illustrated that members of the community played a critical role in assuring young 
people that taking part in a vaccine trial was virtuous. This, in return, boosted the self-
confidence of the participants, as illustrated in Study IV: 
“I am thankful to our teacher [at school] because she was very supportive and 
encouraged us to join in the vaccine trial. Without her we wouldn’t have joined 
the program in the first place. In addition, my mother was very understanding 
and supportive as well” (Informant 8, unmarried female, 23 years old). 
In addition, participants reported that the trial team was available to settle qualms, doubts and 
myths surrounding HIV vaccine clinical trials, expressed by one participant as follows:  
“The trial staff taught us very well, made us understand the whole issue, helped me to 
overcome my fear” (Informant 9, unmarried female, 22 years old). 
In study I, most respondents (86.4%) reported having a significant other who might 
influence their decision. This availability of social support in connection with decision 
making was significantly associated with willingness to participate in the HIV vaccine trials 
among youth (AOR 2.5 (95% CI 1.3-4.9). Whereas, in study III of young girls at high risk 
for HIV infection, only 39% reported having significant others, such as parents or 
guardians, as key people to seek permission from for recruitment and subsequent 
participation in HIV vaccine trials. 
Study II demonstrated the presence of the covert power of community members to 
influence decision making as regards participation in HIV vaccine trials by youth. 
Traditionally, decision making in any major socially and health-related event is viewed as a 
responsibility of elders rather than of young people in a Tanzanian setting. Elders are 
expected to guide young people into making ‘right’ and ‘appropriate’ decisions because of 
their perceived wisdom and years of experience. Likewise, regarding the participation of 
young people in HIV vaccine trials, study participants, including younger community 
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members themselves, felt that young people lacked authority when it came to decision 
making. This observation was expressed as:  
“There is a strong relationship between decisions made by a youth to 
participate in a trial and her/his parents’ support or lack thereof. We would be 
lying if we said a young person can decide independently of his/her parents 
since our young people have not been brought up that way” (FGD 1, 
participant 3, male, age 28).  
Most participants agreed preservation of the habit of involving members of community in 
decision making was an important matter for the successful involvement of youth in HIV 
vaccine trials. Participants reasoned that youth needed harmonious and balanced social 
relations from different key players including spouses and parents in order for them to stay 
focused, maintain psychological well-being and complete the trial schedule.  
Additionally, the impact of community support on participation of youth in vaccine trials was 
a common theme in the narratives of the participants. The study participants said that 
community members would support youth because of the ‘novelty’ of HIV vaccine trials in 
the Tanzanian setting. Participants believed it was the role of community members as parents, 
guardians, friends and peers to help young people facing perceived uncertainties, fears and 
unpleasant effects of participating in an HIV vaccine trial, as stated below:  
“I will encourage young people to join and stay in the trial. I will look for 
information about participants in previous HIV vaccine trials, this information 
will help me to ease their fear that they were the first ones to participate in a 
vaccine trial.” (FGD 7, participant 5, male, age 26).  
In addition, there was strong support extended to participants in the HIV vaccine trial from 
the trial staff, who played a substantial role in informing participants about the process of trial 
participation. Participants reported that the trial team was available to settle qualms, doubts 
and myths about HIV vaccine clinical trials, expressed as follows:  
“The trial staff taught us very well, made us understand the whole issue, helped me to 
overcome my fear” (Informant 9, unmarried female, 22 years old). 
Nevertheless, participants in study II mentioned some attributes that may negatively impact 
the participation of youth in HIV vaccine trials. One was a misunderstanding of the sexual 
behavior of trial participants by members of the community. Study participants wrongly 
perceived and believed that young people participating in HIV vaccine trials would be 
asked to have unprotected sexual intercourse with HIV-infected individuals as part of trial 
to see if the vaccine was working properly or not. One participant expressed this erroneous 
observation as:  
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“People are afraid of a trial because the participants need to have unprotected sexual 
intercourse with an HIV-infected individual to see whether or not the vaccine works” 
(FGD 6, participant 3, male, age 24). 
Other participants mistakenly thought that, as a part of the HIV prevention program, young 
volunteers would be required to abstain from sex during the trial period (Study II). 
Participants were worried that abstinence from sex by young people in adolescence and 
young adulthood was nearly impossible as this was the time they were very sexually active. 
Therefore, instructions like abstaining from sex would make young people less willing to 
volunteer for the trial.  
“It will be difficult for youth to participate if they are told not to have sex because 
most youth like sex” (FGD 7, participant 5, male, age 26)”.  
Another impediment to participation was a fear of the perceived contents of the HIV 
vaccine since study participants had no prior knowledge of HIV vaccine trials (Study II). 
During discussions, it was shown that participants believed that young people might 
experience fear that the vaccine would actually contain HIV, which could infect young 
volunteers:  
“We used to take our children for vaccination, whereby care providers used to inject 
them with medication [vaccine]. The same procedure, getting vaccine injection with 
HIV would be done for young people in the HIV vaccine trials; therefore, young 
people would be afraid to join the trial” (FGD 4, participant 5, female, age 45).  
Since the ability to have children is seen as vital in Tanzanian settings, other participants 
alleged that the HIV vaccine contained things [chemicals] that would purposely interfere with 
the fertility of the young volunteers, thus reducing population growth (Study II). A young 
participant expressed this as follows: 
“Most youth in my community do not trust people from the west because the 
westerners want to get hold of our wealth. The westerners introduce things like 
vaccines with an aim of reducing the native population’s ability to have children” 
(FGD 7, participant 3, male, age 23).  
4.1.3 Community/institutional factors 
Examining the interplay of community factors that may facilitate or hinder participation and 
retention of youth in HIV vaccine trials was one of the important outcomes of this thesis. 
Study IV found that study participants were encouraged to continue being volunteers in the 
HIV vaccine trial, TaMoVac 01, until the end because of the endorsement and management 
of the trial by regulatory bodies such as the Tanzanian Food and Drugs Authority (TFDA) 
and the National Parliament. Such bodies implement laws and guidelines governing the 
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deployment of HIV vaccine trials in order to protect the well-being of trial participants, as 
commented below:  
“I thank our Members of Parliament, who ascertained that vaccine trials conducted 
in Tanzania, neighboring and First World countries were safe. So, the significance of 
the trial among community members has been highlighted and understood to be a 
serious issue” (Informant 12, married male, 23 years old). 
In addition, the support provided by the clinical trial team to participants in Study IV, who 
volunteered for the TaMoVac 01 HIV vaccine trial, played a key role in ensuring that the 
young volunteers finished the trial. The clinical staff centered their work on providing 
standardized information on the processes of each step of the trial. The clinical team provided 
counselling to participants at each clinic visit during the trial in order to settle qualms and 
provided correct answers to myths about HIV vaccine clinical trials among participants, 
expressed as follows:  
“The trial staff taught us very well, made us understand the whole issue, helped me to 
overcome my fear” (Informant 9, unmarried female, 22 years old). 
On the other hand, some participants in study II mentioned stigma as a negative factor for 
participation and retention in HIV vaccine trials. Perceived high-risk behaviors by youth 
coupled with HIV infection and its preventive activities are highly stigmatized matters that 
have adversely affected the uptake of HIV preventive programs in Tanzanian settings. In 
study II, participants thought that, if young people decided to volunteer in any HIV vaccine 
trial, their communities would judge them as promiscuous or, worse, think they were 
infected with HIV. As a result, this sense of perceived stigma led to fearful thoughts of 
isolation from the community should a young person become a trial participant, as 
expressed below:  
“Young people may desire to participate in a trial but they think people would 
judge them as promiscuous since they volunteered for the trial” (FGD 3, 
participant 2, female, age 25).  
“Once people from the community know a young person has been vaccinated 
[become a trial participant], they will think that that person lives with HIV. As 
a result, s/he may be isolated by the community” (FGD 1, participant 3, male, 
age 28).  
4.1.4 Structural factors 
In addition, unemployment and poverty among youth was identified as a hindrance to the 
participation and retention of youth in HIV vaccine trials. Participants in study II observed 
that most Tanzanian youth have poor and tough lives, with low socioeconomic status. They 
stated that despite being of age (18 years and above), young people still depended socially 
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and economically on their parents as a result of unemployment. They might therefore be too 
busy looking for jobs to participate in vaccine trials:  
“Most of the time, youth are busy, looking for means to earn a living. It would 
be difficult for them to leave their daily activities to attend meetings to discuss 
vaccine issues” (FGD 5, participant 7, male, age 23).  
Notably, participants in study II were concerned that most youth were victims of drug abuse, 
making them hostile and violent as well as likely to acquire risky sexual behaviors. 
Participants thought that substance abuse by some young people would not only impede the 
trial but also expose them to HIV. Due to such behaviors, participants felt that such young 
people would be unfit to join the vaccine trials, as expressed below:  
“Most youth are involved in risky sexual activities influenced by injectable drugs, peer 
pressure, alcoholism, and smoking weed. For example, if a young woman receives [a 
vaccine], then drinks excessively, then ends up having unprotected sex, such a volunteer 
would not be able to follow the vaccine trial through to the end because of such 
behavior” (FGD 1, participant 3, male, age 28).  
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5 DISCUSSION 
Once vaccines have been tested for safety in laboratory settings, clinical trials in human 
beings are needed to test their safety, immunogenicity and ultimate efficacy. Having a 
preventive, affordable and effective HIV vaccine would benefit the young people who need it 
the most, particularly in sub-Saharan Africa. This thesis looked at the interaction of different 
actors at the intrapersonal, interpersonal, community and structural level and how this 
interaction influences positively or negatively the recruitment and participation of young 
people in preventive HIV trials. 
Participation of young people in HIV vaccine trials 
5.1 INTRAPERSONAL FACTORS 
5.1.1 Altruism 
Altruistic sentiments were among the factors influencing youth’s recruitment and 
participation in HIV vaccine trials. Young people felt they could sacrifice their body, time 
and effort in order to achieve the greater good, i.e. helping to develop an effective HIV 
vaccine. Their feeling of altruism could have been promoted by knowing the burden of the 
disease in society or by having relatives, friends, family members or peers who had either 
died from or were living with HIV in their community. A study in Kenya revealed that the 
majority of volunteers in HIV vaccine trials were motivated by social benefits, suggesting 
that altruism was one of the major contributing factors in decisions to participate in HIV 
vaccine studies. Respondents’ primary motivator was the desire to contribute to the 
advancement of research which in turn led to improvement in societal well-being, in order 
to help their family, society or the world, This was particularly the case among volunteers 
who often knew of someone infected with HIV/AIDS63. Similarly, in the United States, a 
study among low- and high-risk individuals of African-American origin concurred with our 
finding that altruism was the most prominent factor related to willingness to participate 
(WTP), suggesting that helping one’s community improve the health of its residents was 
the strongest motivator for trial participation64. In addition to the above, the majority of 
young women (29%) in a Microbicide trial in the US and Puerto Rico were motivated to 
join the study for altruistic reasons including “helping other women,” “making a 
difference,” and “contributing to a product that could be life-changing for everybody.” The 
young volunteers thought that helping to empower other women was among the greatest 
motivators, and most emphasized the importance of doing something for others. Some 
enjoyed being part of a project they considered important; for example, it made some 
women feel that they were teaming up with research staff to advance science65. 
For the young female sex workers in the present study, though altruism was mentioned as one 
of the reasons for volunteering in the clinical trial, the nature of their life conditions rather 
than altruistic sentiment could have been an underlying reason for wanting to participate. In 
this group, the participants might have mistakenly thought that the HIV vaccine would have 
protective effects that would prevent them from getting HIV from their sex clients. This view 
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was supported by African-American participants in the study mentioned above, whose WTP 
was highly correlated to perceptions of decreased risk if enrolled in a trial and perceived 
behavioral risk of HIV infection64. It is important for the clinical trial team to have a 
comprehensive and detailed process of informed consent. This process should aim to educate 
participants, in the simplest language, about important aspects and concepts of vaccine trials. 
This will help potential volunteers to decide to join a trial after being made aware of the risks 
and benefits as well as without having false hopes of the vaccine protecting them from HIV 
infection. 
5.1.2 Perceived personal benefit 
5.1.2.1 Regular medical check-up 
In the existing study, some young people joined and completed the HIV vaccine trial because 
they perceived personal benefits such as free, regular medical reviews including HIV tests, 
appointments to see specialists during scheduled visits, provision of contraceptive methods, 
health education to themselves and their spouses/partners and coverage of health insurance 
during trial. Such services were rarely available as part of normal healthcare services. Our 
findings were similar to low- and high-risk participants in the United States, in that those who 
had less healthcare access reported more WTP due to the perceived health benefit of trial 
participation64. In India, financial incentive, life insurance and free medical treatment for 
trial-related illness or injury all had a significant impact on WTP. The promise of access to 
the vaccine for free, if found to be efficacious in the trial, was one of the highest motivators 
among participants. It is important to keep in mind that the concerns among Indian men who 
have sex with men (MSM) might have reflected larger structural factors like poverty and lack 
of access to healthcare rather than logistical challenges or vaccine-specific concerns 66. 
Moreover, among urban American women at high risk of HIV infection, the likelihood of 
willingness to participate in trials was strongly associated with perceived personal benefit 
from an HIV vaccine, suggesting that personal gain would be a strong motivator for 
participation in an HIV vaccine trial that might outweigh general concerns regarding safety or 
possible discrimination. It was pointed out, however, that the decision to enroll in an HIV 
vaccine trial involves complex decision making and consequently the perceived benefits of 
participation must be weighed against realistic consequences67.  
5.1.2.2 Gained confidence 
The young volunteers in the TaMoVac 01 trial became empowered and gained confidence as 
result of participation in the trial. They developed a deeper understanding of health status and 
matured from being fearful of receiving HIV test results to being advocates of spreading HIV 
prevention messages to other young people. The young volunteers were empowered to decide 
safer ways of expressing sexual intimacy that shielded them from HIV infection. Similar 
findings in a social behavioral follow-up study conducted among the adult HIVIS 03 
volunteers between 2 and 3 years after the second HIV MVA boost revealed only 6.1% of the 
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individuals reported extra partners compared to 58.2% of the same cohort interviewed before. 
This suggested that prolonged follow-up counselling was played a useful role in significantly 
reducing the number of extra sexual partners68,69. 
Overall empowerment and transformation of young volunteers in the present study was 
vital to their participation in the HIV vaccine clinical trial because it made them confident 
about their health, about choices of family planning and protection from STIs. Furthermore, 
this transformation may signify the translation of abstract scientific concepts and 
procedures into the practical aspects of real life whereby the procedures that started as part 
of the clinical trial became part of the participants’ practices in life outside the clinical trial 
setting. This was made possible partly because participants received information about such 
procedures through trustworthy and appropriate people at the trial center as seen in South 
Africa and Tanzania70,71. 
Our findings should however be interpreted with caution due to social desirability bias 
whereby participants may underreport actual sexual behaviors and contraceptive practices 
in favor of what the researcher wants to hear. In the course of participation in TaMoVac 01 
trial, some of the young volunteers did not finish the whole vaccination schedule due to 
pregnancy and some male volunteers became fathers. This reflected the dilemma the young 
people had to face in terms of keeping a balance of being trial participant and a parent at the 
same time. 
5.1.3 Vaccine-induced seroreactivity 
Vaccine-induced seroreactivity, VISR, post vaccination posed a challenge in this project i.e. 
routine HIV serological testing could falsely be interpreted as HIV infection rather than an 
effect of the HIV vaccine. Concerns about VISR among those who received HIV vaccines 
emerged notwithstanding several steps to mitigate the impact beforehand. Trial staff 
explained to volunteers what it meant to have VISR, what to expect after it occurred, and 
volunteers were given special identification cards in case they were found to be HIV-positive 
if checked in routine care. In addition, volunteers were offered access to advanced HIV 
confirmatory testing at the trial center. This points to a gap between factual acceptance of trial 
concepts during an informed consent process and the actual acceptance of an untoward 
outcome of the trial when it happens. After all the counselling sessions on the negative effects 
of HIV vaccine, it would be easy to think that volunteers were well equipped to face the 
weight of being falsely HIV-positive, or would be bold enough to convince significant others 
that VISR was nothing to be worried about. Clearly, this was not the case in the present 
study. Volunteers understood and probably accepted the circumstance of being falsely HIV-
positive but when it finally happened, they found it difficult to articulate the concepts of 
VISR or assure spouses, parents, friends and probably care workers that they had VISR due 
to trial vaccine. Their hesitancy and confusion may partly be explained by personal fear of 
unknown effects since the vaccine was on trial, and not much had been documented about the 
reversal of positivity effects, or they were worried about stigma, discrimination and 
abandonment in case everything came out in the open.  
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Our findings of the importance of VISR are supported by results from a long-term follow-up 
study of 287 vaccine recipients in several African countries, where 14 recipients reported 
social harm as misconceptions expressed by parents, partners, neighbors, and clinic staff from 
non-study sites.  Recipients cited positive HIV test results due to vaccine-induced antibodies 
indicating prevalent HIV-infection as the cause of this social harm. Clearly, VISR posed 
problems here leading to discrimination or stigmatization in healthcare institutions, during 
ante-natal care, in blood banks or in relation to organ donation72.  
At the same time, a review conducted in the US on social harm associated with VISR 
included the following: disruption of personal relationships, difficulties in finding or keeping 
employment, difficulties in obtaining insurance, impediments to travel, inability to enlist in 
military, inability to donate blood and organs and inappropriate medical treatment73. It is 
therefore an ethical obligation of trial teams to thoroughly inform and ensure that volunteers 
and people close to them understand and translate difficult trial concepts such as VISR 
throughout trial participation, and if necessary to link them with other medical establishments 
to assure availability of long-term alternative HIV testing to exclude true HIV infection even 
after completion of a clinical trial. 
5.2 INTERPERSONAL FACTORS 
5.2.1 Support from members of the community 
5.2.1.1 Encouragement from members of the community during trial 
Social support systems were a central phenomenon, cutting across recruitment and 
implementation of clinical trials among young people in Tanzanian settings. It was 
observed that having social support from family, peers, friends, guardians, teachers, 
colleagues and members of the community in general was essential for recruitment and full-
length participation of potential young volunteers in clinical trials. In the Tanzanian 
settings, social support through the acceptance of new clinical interventions such as HIV 
trials by members of the community had a major impact on recruitment and ultimately the 
implementation of clinical trials among young people because of existing close kinship 
between young people and the community. Since young people are an integral part of the 
community, they enjoy a sense of belonging such that they still depend a lot on their elders 
for decision making in major life events such as marriage, enlisting in the military, 
attending schools and volunteering in HIV vaccine trials. Young people will seek opinions, 
blessings and permission of the significant others like parents, spouses and guardians before 
deciding to participate, and such opinions will have an influence on the decision to stay in 
the trial until the end. Our findings concur with those in a study performed in the US among 
African-American individuals, which showed that having social support for trial 
participation had a strong association with WTP in Phase- II vaccine trials64. Likewise, in 
India, discussants in focus group discussions (FGDs) described consulting with and even 
getting ‘permission’ from parents and partners as essential to WTP. Interestingly, 
discussants who were financially dependent on parents feared being cut off; and those 
whose parents were financially dependent on them feared becoming ill or injured as a result 
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of the trial and not being able to provide for the family, proving that financial 
considerations link the centrality of family to WTP74. 
However, the majority of female sex workers (FSWs) in the present study were not shown 
to have such well-defined support systems. Participants seemed to be capable of making 
decisions on their own. This stance shown by FSWs in the present study could partly be 
explained by being self-reliant at an early age due to exposure to hard social living 
conditions or by a lack of long-term family or societal ties due to the nature of their work, 
perceived stigma and high mobility. Contrary to our findings, men who have sex with men 
(MSM) in India, who did not live with their parents and were unmarried, expressed reliance 
on the advice of community leaders and community-based organization (CBO) staff, a type 
of surrogate family and high WTP contingent on CBO endorsement74. 
5.2.1.2 Guidance on decision making  
In the same light, members of the community clearly showed influence and interest in 
helping potential young volunteers to join trials. They felt it was their obligation and right 
to influence such decision of young people to participate in trials because they embraced 
the role of parenthood and guardianship in relation to youth. Members of the community 
saw themselves as pillars of support, a place of refuge for youth, and even people to nurse, 
care and pick up the pieces in case some young people fell ill due to the side-effects of trial 
vaccines. In Tanzanian settings, elderly people are regarded as wise and looked upon by 
youth to provide clear direction on certain important life aspects. It is expected that young 
people will listen to and follow the advice provided. Failure to do so would be seen as 
disrespectful, and even in some communities, people believe that going against elders’ 
advice attracts misfortune in life. In China, family support to attend HIV vaccine trails is 
critical. The role of the family in traditional Chinese culture was shown to be an important 
component for WTP in HIV vaccine trials among MSM such that participants who believed 
that their family would support their HIV vaccine trial participation had a significant higher 
WTP75.  
Conversely, the literature shows that members of the community may be not supportive of 
HIV preventive vaccine trials at all times. During the HIVIS 03 study in Tanzania, relatives 
and colleagues at police posts stigmatized, uttered discriminatory comments and showed 
mistrust towards the HIV trial vaccine 68. This suggests that social harm following 
participation in HIV vaccine trials may no longer be an uncommon phenomenon hence 
assessing the frequencies of occurrence, the magnitude, and seriousness of the harm is 
important in order to protect future participants in HIV vaccine trials76. 
More than a third of the 150 women who participated in the Microbicide Development 
Program trial using vaginal gel in South Africa reported cases of intimate partner violence; 
half of which were related to involvement in the trial. Participants described their partners 
as authoritarian, controlling and suspicious of women’s infidelity due to excessive vaginal 
wetness after gel application before sex. Additionally, they reported verbal abuse, 
abandonment, and in some cases, beatings. These findings raised questions as to whether 
trialists conceptualized, understood and addressed everyday domestic violence towards 
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women due to HIV trial participation. This finding further underscores efforts to address 
existing social and gender inequities in communities while empowering women to protect 
themselves from HIV infection at the individual level77.  
Working with communities is one the most principal strategies for the effective 
implementation of any biomedical intervention. Communities motivate governments to 
prioritize HIV vaccine development as part of their comprehensive response. Investing in 
community work would cultivate a sense of community ownership, building trust and 
deepening knowledge of local realities. It could improve the quality of the data collected by 
ensuring that trial protocols, procedures, and strategies are acceptable to trial participants 
and build on locally understood languages and customs76. 
Our findings on WTP among youth from general population and FSWs were slightly 
different in the sense that a higher proportion of FSWs were WTP compared to their 
counterparts (50.6% in study I). Similarly, a study done in China showed that 76.7% of MSM 
were willing to participate in HIV vaccine trials75. However, the likelihood of MSM 
participating in HIV vaccine trials was related to having family support and a desire for 
economic incentives contrary to the majority of FSWs in the current study who wanted to 
participate because of altruism. This high level of WTP shown by our study participants 
could partly be explained by fact that FSWs might have felt they were at a higher risk of 
acquiring HIV infection as compared to other group of youth. Probably, the FSWs 
erroneously thought the vaccine on trial would have a protective effect. Since the efficacy of 
the vaccine is not known at the moment, FSWs would still benefit from other HIV preventive 
packages offered during trial, and this may serve as one of the motivators for trial 
participation. All in all, it is important and an ethical obligation for trialists to inform all 
potential volunteers that it was not known whether the vaccine could protect them or not. 
Therefore, it is extremely important for the volunteers to protect themselves from contracting 
STIs including HIV. 
5.2.2 Mischaracterization of sexual conduct 
5.2.2.1 A lack of sexual inhibition 
Mischaracterization of the reasons for advice on sexual conduct during trial was seen as 
barrier to the uptake of clinical trial interventions by youth. It emerged that many concepts of 
trial procedure were at risk of misinterpretation by both participants and perhaps members of 
the community as well. In the present study, some participants wrongly thought a lack of 
sexual inhibition was a prerequisite for testing efficacy of the vaccine product. FGDs on post-
trial HIV vaccine acceptability among South African youth revealed the most common fear 
expressed by the discussants was that people would have more unsafe sex when they thought 
they were protected by the vaccine. They thought vaccines would discourage condom use, 
increase multiple partnerships, teenage pregnancy and the amount of sexual activity 
occurring. An increase in partner cheating as a behavioral consequence of HIV vaccination 
was raised only in women’s groups. These women appreciated the advances in HIV 
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prevention that a potential HIV vaccine might bring, but they were suspicious of the greater 
relationship insecurity that might accompany such vaccine programs78. Some participants in 
India expressed concerns that an HIV vaccine may actually increase unprotected sexual 
practices and sexual activity more generally but particularly amongst young people who, it 
was implied, would take advantage of availability of such vaccines79.  
5.2.2.2 Fertility issues 
The idea of abstinence from sex during trial as way of preventing HIV and as a means of 
contraception was reported in current study. Having children is an important, almost sacred 
affair in Tanzanian settings, where young people are expected to fulfill their parental roles in 
perpetuating lineage. Therefore, misunderstanding trial procedures and requirements would 
unduly weaken efforts to recruit to and implement HIV clinical trials. Police officers in 
Tanzania voiced concerns over pregnancy restrictions imposed while participating in the trial. 
More often they were concerned about the views of others on the effects of taking part in the 
HIV vaccine trial on their reproductive ability. Both men and women in that study expressed 
a fear of postponing pregnancy and described how they had been subject to negative views 
from others. In addition, young unmarried men without children expressed a loss of 
confidence in the vaccine trial. Although the pregnancy restriction during the trial was 
temporary, the participants in that study expressed fear that the vaccine would affect their 
childbearing ability80.  
Such mischaracterization of trial requirements reported in this study may partly be explained 
by less availability of information about trial procedures in common news platforms such as 
newspapers, televisions, radio and social media. Typically, information about trial procedures 
is provided during the trial period, using physical meetings between potential volunteers and 
clinical staff or found on websites dealing with trials, places not commonly visited by many 
people. In a society like Tanzania, where sexual matters are still considered taboo, i.e. not 
something to be discussed openly, it is imperative to design ways of delivering such 
information in permitted cultural contexts that would not be offensive to anyone or any group 
of people. Since the involvement of the community is important in the uptake of HIV 
preventive interventions, age- and gender-sensitive messages on sexual matters would greatly 
contribute to correcting the mischaracterization of sexual conduct during trials. 
5.3 COMMUNITY/INSTITUTIONAL FACTORS 
5.3.1 Support from research team 
Health care workers and other staff at clinical trial centers formed another essential part of 
the observed support system. The staff in clinical trials were regarded as a bridge between 
scientific interventions and layman’s knowledge of such interventions. The clinical trial 
staff were regarded as key to bringing light and deeper understanding to hard, scientific 
concepts used in clinical trials, to dispel myths and misconceptions about HIV vaccine 
trials, to counsel on anxieties and worries raised by young people and their significant 
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others. The staff constantly monitored trial participants via mobile phones or by paying 
physical visits to the areas where participants lived. Kenya observed a high retention rate 
ranging from 90% to 96% in HIV trials in four Phase I/II clinical trials among healthy, 
adult, HIV uninfected volunteers. The research team attributed the high retention rate in 
four trials to the informed consent process whereby individuals’ questions were answered 
comprehensively and recurrent volunteer education on the trial procedures was carried out 
during follow-up visits. Further, many contacts between potential volunteers and the study 
team prior to enrolment facilitated good rapport and trust between the two, hence enhancing 
volunteers’ retention in the study. Also, it was possible that the medical care given to 
volunteers for all the adverse events might had contributed to the good follow-up rate81. 
Interestingly, frontline health service providers (FHSPs) working with MSM and FSWs in 
India felt that the relationships they developed through close interactions with FSWs and 
MSM placed them in an ideal position to take part in vaccine trials and rollout programs as 
an extension of their responsibility as FHSPs. Further they thought their long-term rapport 
with community members would enable them to maintain communication channels during 
clinical trials so as to ensure the ethical conduct of clinical trials and the implementation of 
future HIV vaccine delivery programs79. 
In contrast to our findings, a higher proportion of FHSPs working with key populations in 
India reported a lack of belief in vaccines and a preference to promote other HIV prevention 
strategies. This reflected health service providers’ familiarity with on-the-ground realities that 
pose obstacles to vaccine uptakes or acceptability among key populations. In the same study, 
7.5% of third line health service providers, HSPs, expected difficulties in convincing 
members of key populations to receive a future HIV vaccine, suggesting poor communication 
between HSPs and key populations, so that HSPs did not feel that it was worth their while to 
convince community members to accept an HIV vaccine82. 
A follow-up study among HIVIS 03 volunteers in Tanzania showed a decrease in mistrust 
towards HIV vaccine trials over time. The implication of the findings was that the 
community increasingly understood the logic behind HIV vaccine trials68. But an alternate 
explanation would be that volunteers might have demonstrated confidence and 
assertiveness while dealing with the mistrust as revealed in a previous study of their 
experiences as volunteers in HIV vaccine trials83.  
5.3.2 Support from regulatory institutions 
The role of regulatory institutions like Food and Drug Authorities in Tanzania84 was critical 
for gaining the trust of potential and actual young volunteers in clinical trials and hence make 
it easy to recruit and retain volunteers in HIV vaccine trials. It is worth noting that the 
regulation of clinical trials in many lower- and middle-income countries like Tanzania, where 
some HIV vaccine clinical trials are taking place, is still new and evolving. In some countries, 
regulators are primarily pharmacists and often they have more of a pharmaceutical 
background and are less experienced with vaccines or biologicals85. Likewise, HIV 
preventive clinical trials in Tanzanian settings are a relatively new undertaking that is viewed 
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suspiciously since its origins are mostly in Western countries. Young people and the 
community in general can mistakenly perceive such interventions to have bad intentions, i.e. 
cause detrimental health outcomes such as the impaired ability of young people to reproduce. 
In conjunction with that, WHO recognizes and acknowledges scientific challenges posed by 
the clinical development of prophylactic HIV/AIDS vaccines due to many unknowns in the 
field, such as diversity of legal and ethical frameworks, lack of human survivors, and 
considerable viral genetic or strain variability85. Therefore, having international 
harmonization and standardization of regulatory practices will help to ensure that HIV 
vaccines are evaluated and licensed based on internationally accepted scientific criteria and 
standards85. This will not only send a message to the community that protecting the health of 
Tanzanian young people is the utmost priority but also will ensure that the government 
adheres to standard guidelines of ethical, regulatory requirements when conducting any 
clinical research using human subjects. 
5.3.3 Stigma 
The presence of perceived stigma associated with HIV and its preventive activities in 
Tanzanian settings is one of the social risks posed to young people participating in HIV 
vaccine trials. Despite current HIV prevention programs in Tanzanian settings, stigma 
exists because the main mode of HIV transmission is sexual, which is associated with 
promiscuity. Promiscuity is also linked with flawed thoughts of increased sexual activities 
happening in adolescence and young adulthood as young people experiment sexuality. In 
our study, members of the community said that HIV infection and its preventive activities 
had been stigmatized because HIV infection is seen as a disease with no cure, a shameful 
condition associated with promiscuity, as a source of unrelenting suffering and death. Our 
findings showed that young people would have a hard time deciding to join HIV preventive 
trials in order to avoid unnecessary consequences of discrimination. In support of our 
findings is a study in Kenya among peer leaders, community advisory board members, 
former and current volunteers in clinical research, study staff, community leaders and 
community members. This study found that opinions about and willingness to participate in 
HIV-vaccine research of potential volunteers were negatively shaped by stigma and 
discrimination in families and the community. The respondents feared experiencing stigma 
or discrimination given the strong perception among all respondents that being a HIV 
vaccine study volunteer was widely equated with being HIV-positive. Gossip, finger-
pointing and casting accusations about moral character were a salient concern among 
respondents and women were more vulnerable to accusations of infidelity, violence and 
abandonment86. Likewise, a study among MSM in India revealed that there was stigma 
operating at the community level. This was expressed as fears of being looked down upon 
by one’s peers as one who engages in sexual risk behaviors or is HIV-positive. As a result, 
potential volunteers who were motivated by altruism and wanting to give back to their 
community changed such motivations into liabilities74. This level of stigma in the present 
study shows poor knowledge of HIV and its preventive methods, further demonstrates 
deep-seated fears of contracting HIV due to a lack of permanent cure for the disease. 
Tackling stigma using tailored, gender- and age-specific educational messages about HIV, 
its transmission, prevention methods and antiretroviral therapy (ART) would help to 
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improve the situation at family and societal levels. This would hopefully result in 
acceptance, without prejudice, of new HIV preventive interventions, including HIV vaccine 
trials in Tanzanian settings. 
5.4 STRUCTURAL FACTORS 
5.4.1 Poverty and unemployment 
Poverty and unemployment among youth were factors hindering trial implementation 
because young people would not be able to adhere to trial schedules. Looking for 
employment would be their primary interest over making scheduled clinic visits to receive 
HIV vaccine. It would therefore be difficult for them to concentrate on trial procedures. Most 
unemployed young people would be at risk of joining street gangs or selling drugs in order to 
make living. This would jeopardize their personal safety, would cost clinical teams in time 
invested, diminish derived health benefits and lead to an inconclusive outcome as regards 
vaccine testing. Young people could be advised to pursue vocational training programs that 
enable them to become self-employed as part of solving unemployment and poverty. In future 
trials, the trialists could liaise with different stakeholders who provide life skills interventions 
to marginalized youth not only to get young people off the streets but also to inspire some 
youth to become potential volunteers in future HIV vaccine trials. 
5.4.2 Substance abuse 
Concerns about substance abuse among young people were expressed by members of the 
community. Use of illicit drugs among young people had been rampant in peri-urban and 
urban areas in Dar es Salaam because of idleness, peer pressure, fashionable trends and other 
youth considered it as a way of earning living. This lifestyle exposed young people to the 
dangers of drug addiction leading to mental illnesses, inability to keep jobs or work normally, 
exposure to criminal prosecution, and acquisition of STIs including HIV infection. According 
to 2011 and 2012 National Survey on Drug Use and Health data in the US, nearly 27 and 12 
million young adults aged 18 to 25 drank alcohol and used an illicit drug in 2012 
respectively. Of those using illicit drugs, 3.2 million used marijuana, 57 304 used heroin and 
51 319 used cocaine87. In Germany, a review of data on the prevalence of addictive behaviors 
from ten national surveys and one regional survey conducted between 2002 and 2012 among 
adolescents (11-17 years) and young adults (18-25 years) revealed some strong associations 
still existed between social inequalities and the prevalence of substance use. Low 
socioeconomic status (school type, employment status) was consistently associated with more 
cigarette smoking and problematic patterns of alcohol consumption were significantly more 
prevalent among young unemployed males compared to secondary high school/grammar 
school students of the same age. In terms of the consumption of cannabis, the unemployed 
and students with a low educational level emerged as high-risk groups88. In phase I and II 
clinical trials, potential volunteers need to be healthy, HIV-negative individuals, with low a 
risk of exposure to HIV infection. Therefore, recruitment and follow-up of young people who 
abuse drugs would pose a challenge due to the likelihood of exposure to HIV, leading to false 
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conclusions about the vaccine on trial. Surprisingly, an assessment of the patterns of 
substance use and its impact on retention of volunteers in phase 1 preventive HIV vaccine 
clinical trials among enrolled participants from 10 HIV Vaccine Trials Network phase 1 
preventive HIV vaccine clinical trials, conducted between February 2009 and September 
2014 in the Americas and Switzerland, found neither frequency of alcohol use, binge 
drinking, marijuana, nor other drug use negatively impacted retention and adherence rates in 
those clinical HIV prevention trials. It is worth noting that evidence pointed to trial 
participants engaged in binge drinking behavior being associated with higher rates of 
unprotected sex, which might have been an indicator of an increased risk for acquiring HIV89. 
Age- and gender-specific risk reduction counselling should be part and parcel of all 
participant preparation in any HIV vaccine trial. 
On the other hand, in phase III efficacy HIV vaccine trials, young people who inject drugs 
would be ideal participants as such trials would recruit participants with high-risk behaviors 
that would continually expose them to HIV infection. The literature suggests that injecting 
drug users (IDUs) should and could be recruited for HIV vaccine trials because HIV 
prevention is their human right to health and a public health imperative. To ensure that 
prevention methods are safe, efficacious, and accessible to this population, novel prevention 
strategies and approaches must be assessed from this community’s standpoint, hence IDUs 
must participate in HIV preventive research90.  
There is well-documented evidence of the challenges of having IDUs as trial participants, 
such as stigma, discrimination, criminalization, harsh policing practices, inaccessibility of 
sterile injecting equipment, the prevalence of comorbidities such as viral hepatitis and 
mental health illness, lack of access to basic services, high unemployment rates, an overall 
lack of respect for the basic human rights of people who inject drugs90 as well as trial 
specific challenges such as cost, requirement for multiple doses, and limited time91. It 
therefore suffices to say the recruitment of such individuals to trials should vigilantly 
follow criteria stipulated in protocols to ensure maximum participation of potential 
volunteers in Tanzanian settings.  
The trialists must fulfil an ethical obligation to ensure young people protect themselves 
from acquiring HIV at any cost, despite their drug use habits. Most of all, there is a need for 
a multi-sectoral approach to dealing with the use of unsafe illicit drugs so as ensure young 
people and nations are safe from drugs. 
5.5 METHODOLOGICAL CONSIDERATION 
5.5.1 Validity 
Validity is ability of a measuring instrument to give a true measure, i.e. how well it measures 
what it purports to measure92. In study I, we ensured internal validity by designing 
questionnaires with questions that were borrowed from other research studies. We conducted 
pilot testing of the data collection tools in order to clear up ambiguities, to assess 
understanding of respondents of concepts/questions and to check the time taken to fill in the 
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questionnaires. We also ensured that our respondents were sampled systematically to remove 
sampling bias. The validity was not fully realized in assessing perception and knowledge of 
HIV vaccine studies among youth due to use of some unvalidated data collection tools. At the 
time of developing the research protocol, there was limited literature on assessing those 
concepts with reference to factors affecting willingness of youth to participate in HIV vaccine 
trials in Dar es Salaam. We therefore designed questions to address those concepts on our 
own and pilot-tested them. In the analysis, we conducted internal consistency analysis that 
found that questions designed to assess perception and knowledge had low internal reliability 
and our findings should therefore be interpreted with caution. Yet, we decided to include 
them in our results because of their importance with regard to adding information to the small 
amount of literature that was available on this topic. 
External validity implies the ability to generalize beyond a set of observations to some 
universal statement92. Since the study was conducted among youth seeking care at IDC, the 
application of findings could be limited to young people in similar settings. On the other 
hand, the study provided insights into, e.g., the role of significant others in HIV vaccine 
participation, a theme which had been discussed in other HIV vaccine research studies among 
adults and youth in different contexts 74,83. Therefore, even if it has some limitation, it is 
worth considering some of the implications in a broader context. 
5.5.2 Non-probability sampling  
Usual census data do not include all information about key populations due to illegality and 
criminalization of their lifestyle. they are therefore not included in the population survey data. 
There is no sampling framework for FSWs in Tanzania that can be used to draw our sample. 
Therefore, the surveys are non-probability, which means that each member of population has 
an unknown probability of being sampled. Several sampling methods for key populations 
have been documented such as venue-based sampling, targeted sampling, time location 
sampling; referral-based methods such as convenience sampling of known, most at-risk 
populations, snowballing sampling along networks and respondent-driven sampling (RDS)93. 
For our study, we used RDS because it is a probability-based sampling method that uses 
long-chain peer referral to penetrate sub-networks of hidden populations93 . We also used 
RDS so as to be able to infer our findings to the study population. In RDS, though 
recruitment starts as snowballing by giving coupons to seeds, it differs from snowballing in 
that the number of coupons given to seeds and subsequently referred participants is limited so 
as to minimize effect of over- or under-sampling of individuals. In our study, we limited 
coupons to three. Furthermore, RDS draws its statistical basis from First Order Markov 
theory whereby, if the recruitment has more waves of recruitment, it will have longer chains 
of recruitment so that the final sample of individuals recruited to the study will not have 
similar characteristics to the seeds or original recruiters, reflecting equilibrium. When the 
state of equilibrium is reached, the final sample can be inferred to the population from which 
the sample population was drawn93. During analysis in the present study, the RDS analytic 
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tool considered weights from recruitment patterns and reported network sizes of respondents 
in order to adjust for under- or over-representation of individuals in the study.  
5.5.3 Low rate of coupon transfers  
Coupons were slow in being used, which resulted in the ‘death’ of some seeds early on 
during data collection leading to an increase in the number of seeds in order to reach 20. One 
of the reasons for the poor redemption of coupons in the present study was a fear among 
young FSWs to approach health facility where the study was being conducted because there 
was a general crackdown on key populations and their activities at the time of data collection. 
The respondents feared being captured by the local authorities and thrown into jail. They 
thought the authorities were using health facilities as a new strategy for identifying and 
capturing them. So, they failed to refer their peers in time, i.e. before the expiry date on the 
coupons. Therefore, in order to reach our sample size, we had to review recruitment data 
periodically and increase the number of seeds by calling those who had participated in 
formative research sessions. 
5.5.4 Incentives  
RDS employs a dual incentive system in which one is reimbursed for time and transport as a 
study participant. The same individual will be reimbursed as a recruiter after recruiting 
eligible peers within a stated timeline. It is possible that participants could be coerced into 
participating in the study or even bring ‘coached’ peers, meaning people who do not really 
belong in the same network or do same activity so as to receive double incentives. We 
minimized this risk by setting a reasonable amount of money that would not be source of 
coercion. A formative study was conducted prior to the current study. Among other things, it 
determined a range of reasonable amounts of money to compensate the study participants for 
time spent travelling to and from clinic and at the clinic during the research and for every 
peer referred. The proposed amount was further reviewed and discussed during ethical 
approval processes, and a final amount was approved by MUHAS Institutional Review Board 
and researchers. Further, at the clinic, recruitment manager conducted screening 
questionnaires for eligibility. 
5.5.5 Social desirability  
Social desirability is when a participant answers study questions in a way that s/he knows is 
what research wants to hear. This may lead to under- or over-reporting of outcomes of 
interest in the research. In studies I and III, we used self-administered questionnaires to give 
participants room for privacy and confidentiality in filling questionnaires. However, we asked 
the participants sensitive questions about sexual behaviors, and there was a chance that 
participants had under-reported in study I or over-reported in study III. In study I, young 
people were recruited from the general population, so they probably were not too comfortable 
about revealing their actual risk behaviors hence they under-reported them. In study III, the 
participants had already been “labelled” as female sex workers, as a result they might had 
exaggerated their responses with regards to risk behaviors. During the interviews, the 
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researchers addressed and interacted with the respondents respectfully, so as make them 
comfortable, then assured them complete confidentiality in the research process. Finally, the 
research team encouraged them to fill in questionnaires as best they could. 
5.5.6 Trustworthiness/validity  
Validity in qualitative research or trustworthiness is a concept that explains how sound and 
good quality the study is. Validity establishes truth, value and authenticity of the study94. In 
this thesis, trustworthiness has been discussed in the following aspects: 
5.5.6.1 Credibility 
Credibility refers to the ability of research outcomes to really capture multiple realities of 
the study participants. It describes how well investigators managed to reconstruct the 
subjective realities of study participants, if the study participants would recognize those 
subjective realities in outcomes and finally, if other people in different contexts could relate 
to such realities in final reports95.  
5.5.6.2 Triangulation 
Triangulation is the combination of multiple observers, theories and data sources 
(researchers) hopefully to overcome the intrinsic bias that comes from single methods, 
single observers, and single theory studies96. The logic behind triangulation is based on the 
premise that no single method ever adequately solves the problem of rival explanation, 
since each method reveals different aspects of empirical reality97. 
In this thesis, triangulation was addressed by using both quantitative and qualitative 
research methods. Quantitative methods were used to quantify and provide a clear 
description of the problem and its possible determinants. Combining with qualitative 
inquiry, meanings and understanding of concepts and descriptions were realized. 
Triangulation of methods of data collection refers to the combination of different methods 
in studies while triangulation of data sources refers to different study participants and 
triangulation of investigators means using more than one investigator95. For instance, we 
used questionnaires in study I which gave rise to insights into the role of significant others 
in HIV vaccine participation among youth. Detailed answers were provided by using focus 
group discussions in study II. We further used in-depth interviews that elicited experiences 
of young volunteers in trials that gave more insight into WTP in HIV vaccine trials. We 
also collected data using FGDs from young people with diverse characteristics and 
background, along with some adults. Further, the studies had been conducted by team of 
international researchers that have different backgrounds, experiences and disciplines in 
research methodologies; medical, nursing, global health, and the HIV vaccine clinical trials.  
5.5.6.3 Peer debriefing 
Peer debriefing means presentation of preliminary findings to colleagues,  allowing 
researchers to evaluate their work, and receive input from those outside the research 
process95. In this study, peer debriefing took place after data collection and analysis of 
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preliminary findings. We presented the initial findings to other investigators and staff at 
IDC for critical review, discussions and understanding of the preliminary results. Then the 
investigators provided feedback and comments that helped to shape final discussions and 
design research questions for the subsequent studies. For instance, preliminary findings in 
study I paved the way for an improved design of study II. 
5.5.6.4 Member check 
Member check entails feeding back the results to the members of the studied group. This 
process clarifies the information provided and confirms the researchers’ interpretation95. 
The results of study IV were presented to some participants so as to see if our 
interpretations of findings represented their original thoughts. Most of them agreed that the 
interpretations reflected their thoughts on the readiness of youth to be involved in HIV 
vaccine trials. 
5.5.6.5 Reflexibility 
Reflexibility describes a journey of discovering how the researchers shaped and how they 
were shaped by the research process. The researchers acknowledged the changes brought 
about in themselves as a result of the research process and how these changes have affected 
the research process98. Reflexivity involves a process of on-going mutual shaping between 
researcher and research. Simply put, reflexivity concerns itself with the effect of the whole-
person-researcher on the research as well as the effect of the research on the researcher. 
Reflexivity seeks to help researchers grow their capacity to understand the significance of 
the knowledge, feelings, and values that they brought into the field to the research questions 
that they came to formulate, to the analytical lenses that they chose to employ, and to their 
findings. The role of reflexivity involves raising awareness of processes of research with 
the dual aim first of enriching one’s lived experience, and then articulating this awareness 
as a contribution to the deepening of understanding of the field99. 
Being a young optimistic researcher, parent, doctor and PhD candidate in research 
fieldwork has left me with a deeper understanding and appreciation of the complexities of 
looking for permanent cure for HIV. I was dealing with some young female volunteers in 
the trial who experienced marital discordance following participation in the trial. As a 
young parent and female, I was devastated to see what those young people went through. I 
was afraid for their future since it was uncertain if their marriages would work out or not. 
However, during counselling sessions with them, as a result of my training, I could show 
them empathy rather than sympathy in order to ensure I played my role as a counsellor in a 
professional and ethical manner. At times, I was frustrated to see young people in the trial 
got pregnant or become expectant fathers, in my mind I thought that they were not serious 
enough and could not see how important HIV vaccine research was. Over time, by listening 
and working with them, I came to appreciate the dilemmas, personal griefs, sacrifices, 
worries and choices the volunteers went through to reconcile their participation in the 
clinical trial with their lives in their communities. It taught me that there were multiple 
factors and realities in play for any clinical intervention to succeed or not. During data 
collection using in-depth interviews, I was worried that young volunteers would give 
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answers that I wanted to hear for fear of disappointing me or for fear that I would see them 
differently after all the years of interaction at the trial site. Through my PhD training, I was 
able to establish a good rapport, explaining my role as a researcher, assuring them of 
privacy and confidentiality. Then by using a semi-structured interview guide, I was able to 
probe, monitor and obtain fairly good answers to questions about their experiences of being 
young volunteers in the TaMoVac I trial. During data analysis, coding and creating 
categories and themes was wearying and draining. I used to worry that abstracted 
information from interview texts and discussions would not really reflect and represent the 
ideas and concepts of the participants. Under the guidance of qualitative experts, AK and 
EAMT, I learnt that data analysis was not mere coding and abstraction, but also entailed 
listening to audios, reading texts, ensuring translated texts had all the meaningful 
information, and at the same time being professional researcher by conducting analysis that 
followed scientific methods. The process taught me how to disengage my a priori ideas or 
interpretation and extract emergent themes from collected data. Having that experience 
enabled me to formulate themes and arrive at conclusions that not only answered research 
questions but also added knowledge to the research topic. 
5.5.6.6 Transferability 
Transferability refers to the application of research findings to other contexts95. To allow 
transferability, the researchers must provide sufficient detail of the context of the fieldwork 
for a reader to be able to decide whether the prevailing environment is similar to another 
situation with which he or she is familiar, and whether the findings can justifiably be 
applied to this other setting. It is also important that a sufficiently detailed description of the 
phenomenon under investigation is provided to allow readers to have a proper 
understanding of it, thereby enabling them to compare the instances of the phenomenon 
described in the research report with those that they have seen emerge in their situations. In 
order to assess the extent to which findings may be true of people in other settings, similar 
projects employing the same methods but conducted in different environments could well 
be of great value100. 
In this thesis, we observed scientific methods from proposal development to data collection 
and analysis at the same time as adhering to the ethics of research work. Furthermore, final 
articles, abstracts and reports had to clearly describe background information, 
methodological steps, results and discussions in order to allow readers to make valid 
informed conclusion if our findings could be applicable in their settings. For instance, the 
young volunteers in HIV vaccine trials in this thesis had fears of vaccine-induced 
seroreactivity, and the same impressions were found in volunteers in HIV vaccine trials in 
the US, Belgium, Kenya, South Africa, Rwanda and elsewhere. 
5.5.6.7 Dependability 
In addressing the issue of dependability, researchers need to demonstrate techniques that 
show that, if the work were repeated, in the same context, with the same methods and with 
the same participants, similar results would be obtained. In order to address the 
dependability issue more directly, the processes within the study should be reported in 
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detail, thereby enabling a future researcher to repeat the work, if not necessarily to gain the 
same results100. In this thesis, we clearly described research plans and ways of their 
implementation. After seeking permission from the participants, we used audio tapes to 
record the in-depth interviews and discussions in focus groups. In addition, during data 
collection, we took notes for impressions, for jogging memory on certain emphasized 
points during discussions, record-keeping and reference during write-ups.  
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6 CONCLUSION 
Youth showed readiness to participate in phase IIa HIV vaccine trial. For most young 
people, the decision to participate in vaccine trials largely depend on support of members of 
the community. In contrast, for high-risk young women, this decision largely be their own. 
Some factors like altruism, support from members of the community and, perceived 
personal benefit served as positive attributes to participation. Despite such readiness, 
fertility issues, stigma, poverty were perceived as hurdles needed to be resolved by different 
stakeholders on individual, community and societal levels for successful participation. 
7 RECOMMENDATIONS 
Practical aspects 
o Increase awareness of health professional such as nurses, laboratory 
technicians, phlebotomists and clinicians on the existence of clinical trials, 
their roles in supporting volunteers in health facilities.  
o Increase understanding among members of the community such as parents, 
guardians, youth organizations and peers of the trial process, concepts and 
advocate for their support of HIV vaccine trials. 
o Advocacy to develop guidelines on inclusion of significant others and other 
members of the community in clinical trials involving young people. 
o Conduct scheduled meetings with volunteers and significant others for 
regular updates on the progress of clinical trials locally and globally as a 
retention strategy. 
Research Aspects 
• One of the studies in this thesis provided some background information about 
female sex workers and willingness to participate in HIV vaccine trials. This is 
information that could be used to design future efficacious HIV vaccine trials in key 
populations. Hence, the following research studies should be considered: 
o Studies of socioeconomic inequalities among young people in key 
populations in HIV vaccine research programs and how inequalities may 
impact their participation in trials 
o Perspectives of health care workers and policy makers on participation of 
high-risk youth in HIV vaccine research programs 
o Longitudinal cohort studies among youth in key populations to establish 
HIV incidence. 
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